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Abstract
Peripheral nerve blood flow (NBF) is critical to nerve health. Impaired NBF control
may contribute to the progression of diabetes peripheral neuropathy. The purposes of this
dissertation were: i) to investigate the acute and chronic effects of hyperglycemia on basal
sciatic NBF (measured via Doppler ultrasound), ii) to examine the potential vasodilatory
effects of insulin (euglycemic hyperinsulinemic clamp; 10 mµ•kg-1•min-1) on NBF control in
healthy rats and rats with insulin-treated type 1 diabetes (DS) and iii) to determine if exercise
training (~75% VO2max, 60 min/day, 5 days/wk for 10 wk) improves vasa nervorum
reactivity to insulin and motor nerve conduction velocity (MNCV) in rats with DS. The
studies tested the overall hypotheses that i) basal NBF, the vasodilatory response to insulin,
and MNCV would be attenuated in rats with DS, and ii) DS-induced deficits would be offset
by concurrent exercise training. Rats with DS were hypertensive and featured reduced
MNCV (P<0.01). However, DS did not alter: basal NBF; the relationship between NBF and
blood pressure; or the vascularization of the sciatic nerve compared to healthy controls
(P≥0.50). Based on these data, hypertensive rats with DS may exhibit elevated NBF in the
conscious, basal state (P=0.02). Despite similar or possibly elevated basal NBF values
compared with control rats, rats with DS displayed impaired insulin-mediated vasodilation
(P≤0.01). Deficits in insulin-mediated vasa nervorum dilation and MNCV were prevented by
concurrent endurance exercise training in a separate group of rats with DS. Enhanced
insulin-mediated vasa nervorum dilation in aerobically exercise trained rats with DS may be
explained partially by the observed increase in sciatic nerve endothelial NO synthase
expression (P=0.04). The degree of hyperglycemia was similar in both groups with DS, but
exogenous insulin requirements were reduced in rats with DS that exercise trained (P=0.02).
Perhaps increased insulin sensitivity, and not reduced hyperglycemia, is the mechanism
responsible for preserving vasa nervorum and nerve function in exercise-trained rats with
DS. Improved insulin signaling in the vasa nervorum may potentiate insulin signaling in the
sciatic nerve and protect against diabetic peripheral neuropathy.
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Chapter 1

1

« Introduction »
1.1

General perspective

To combine in a systematic method, the phenomena that together constitute the
existence of living beings, and to organize, compare and contrast such phenomena to
form generalizations or principles regarding physiological functions and their regulation
is the domain of the Integrative Physiologist (1). As such, the objectives of this
dissertation were fourfold: 1) to consolidate the available information pertaining to blood
flow control in arteries that supply peripheral nerves, 2) to provide the context necessary
to understand and justify the research projects described herein and 3) to participate in the
process of discovery and 4) to produce novel and meaningful research that extends upon
current understanding. Prior to a more thorough dissection of the literature, an elementary
outline of the nervous and cardiovascular systems, as well as diabetes and the vascular
etiology of diabetic peripheral neuropathy, is requisite.

1.2

Nervous system

The nervous system is composed of the central and peripheral components. The
central nervous system consists of the brain and the spinal cord. The brain is responsible
for receiving, integrating and coordinating activity in all parts of the body and the spinal
cord serves primarily as the conduit of information between the brain and peripheral
nervous system. The peripheral nervous system includes afferent sensory neurons that
relay information from peripheral receptors to the central nervous system, as well as
efferent neurons that transmit information from the central nervous system to peripheral
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tissues. The somatic nervous system is a branch of the peripheral nervous system and
conducts impulses from the central nervous system to skeletal muscles. The autonomic
nervous system is the second branch of the peripheral nervous system and conducts
impulses from the central nervous system to organs of the body as well as cardiac and
smooth muscles (i.e. blood vessels). Nervous tissue is highly active and requires a
continuous stream of blood flow to supply the nutrients necessary to function properly
(2).

1.3

Cardiovascular system

The cardiovascular system consists of the heart, arteries, capillaries and veins.
The heart is the primary source of impetus for blood flow. Oxygenated blood from the
left ventricle of the heart is distributed throughout the body by arteries and smaller
arterial branches called arterioles. The arterioles branch into smaller blood vessels called
capillaries and this is where the bulk of nutrient and gas exchange between the blood and
surrounding tissues takes place. The capillaries feed into venules, the venules converge to
form veins and these veins transport deoxygenated blood to the right atrium of the heart.
Once returned to the heart, deoxygenated blood is pumped into the pulmonary circulation
to become re-oxygenated. Thereafter, oxygenated blood returns to the heart and is redistributed throughout the body. The cardiovascular system provides tissues with a
continuous stream of nutrients including oxygen and removes metabolic byproducts away
from the site of energy use. Blood flow distribution is influenced by tissue specific
control features which rely on a multitude of inputs including mechanical factors as well
as neurogenic and metabolic stimuli (2). A detailed description of the blood supply and
blood flow in the sciatic nerve will be provided later (Chapter 2).
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1.4

Type 1 diabetes and peripheral neuropathy

Type 1 diabetes is an autoimmune disease characterized by the destruction of the
insulin-producing beta cells of the pancreas. The net result is a decreased ability to
produce insulin which leads to elevated blood glucose concentrations (hyperglycemia)
(3). Other classical symptoms include increased thirst (polydipsia), frequent urination
(polyuria), the appearance of glucose in the urine (glycosuria), increased hunger
(polyphagia) and weight-loss. Although many options are available, the primary
treatment for type 1 diabetes is supplemental insulin (3). Insulin treatment helps attenuate
hyperglycemia, but tight blood glucose control is difficult to maintain chronically (3,4).
As a result of poorly controlled blood glucose (or potentially the lack of insulin),
individuals with type 1 diabetes are at an increased risk for developing both vascular
disease and peripheral nerve dysfunction (5). Accordingly, researchers have proposed a
vascular etiology of diabetes peripheral neuropathy. Specifically, the theory states that
episodic or sustained hyperglycemia impairs microcirculation in peripheral nerves and
over time this culminates in nerve dysfunction (6,7). Hyperglycemia may be caused by
excess glucose production or ingestion as well as insufficient insulin to stimulate tissue
glucose uptake or impaired insulin signaling. Individuals with poor glycemic control are
at a greater risk of developing vascular disease and diabetic peripheral neuropathy;
therefore, treatments that enhance insulin signaling or sensitivity in the microcirculation
of nerves may help prevent such diabetes-related complications.

1.5

The blood supply of nerves

By the early 1900s the gross anatomical and morphological aspects of peripheral
nerve blood supply (vasa nervorum) had been described. These observations generated
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great interest regarding the functional significance of the vasa nervorum. Detailed
historical perspectives that also serve as research summaries are available (8–10);
therefore, only a brief account of the historically relevant background information will be
provided.
Whereas the early literature (1627-1756) noted the existence of the vasa nervorum
(11–14), it was not until 1768 that Isenflamm and Doerffler (15) devoted an entire body
of work regarding its potential significance to neural health. Of note, they were able to
provide an anatomical description of the epineurial vascular network by filling the
arteries with wax. Approximately one-hundred years later (1859 & 1864), Hyrtl provided
the first series of critical discoveries in two papers (16,17) and among other findings
established that:
i)

each nerve contains feed arteries that do not branch into surrounding
muscle beds,

ii)

the nerve supply arteries contain ascending and descending branches that
form a continuous longitudinal anastomose between adjacent nerve
supply arteries.

These observations raised the possibility of collateral circulation.
By the late 1800s similar anatomical observations were made by others (18–20),
and with a more clear understanding of the nerve vasculature scientists were able to
generate more specific hypotheses regarding the significance of the vasa nervorum and,
as a result, employ more appropriate experimental models. At the time, understanding
was that impaired circulation or nerve vascularity would compromise nerve function and
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recovery from insult (18,21–23). Generally speaking, two experimental models were used
to test these hypotheses, namely, nerve compression and arterial ligation. Although the
results between studies vary (24–28), perhaps owing to differences in experimental
design, in his 1957 review, Blunt suggested that occlusion of regional neuronal arteries
may result in profound histological changes in the nerve and impair nerve regeneration
following injury (9). Later he confirmed this position and demonstrated experimentally
that ischemia results in neuronal degeneration (29).
Around the same time the relationship between ischemia and nerve degeneration
was being unraveled (~35 years after the discovery of insulin), in the late 1950s
Fagerberg was among the first to hypothesize a vascular etiology of diabetic peripheral
neuropathy formally (6,30). He proposed that in patients with type 1 diabetes mellitus,
sclerosis of nerve supply arteries may result in ischemia and subsequently nerve damage.
Shortly afterwards, the observation of diabetes-induced platelet abnormalities in the
blood (31) and vasa nervorum fibrin accumulation (32), strengthened Fagerberg’s
position. However, at this point a direct link between nerve blood flow (NBF) and
diabetes had not been documented. Then in 1984, a hallmark study published by Tuck
and co-workers (7) demonstrated for the first time that sciatic NBF was reduced in rats
with untreated experimental diabetes (rodent model of type 1 diabetes). In rats with
experimental diabetes (i.e. limited ability to produce insulin, no insulin treatment and
chronic severe hyperglycemia), reductions in sciatic NBF occurred alongside decrements
in oxygen content of the nerve and nerve dysfunction. These data confirmed over 200
years of hypotheses and speculation by linking reduced NBF with ischemia and nerve
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dysfunction (7). This paper continues to serve as the foundation for studies investigating
the effects of glucose, insulin and diabetes on NBF control.

1.6

Glucose, insulin and blood flow control

Early after the discovery of insulin (33), it became known that insulin
administration and the subsequent hypoglycemia increased heart rate and reduced blood
pressure (34,35). The possibility that insulin-hypoglycemia might alter peripheral blood
flow had not received much attention until Abramson and colleagues (36) published a
study in 1939, describing insulin-stimulated vasodilation in the human forearm and calf.
In this study, they also noticed greater vasodilation in the lower vs upper limb and that
the magnitude of vasodilation was attenuated if there was a reduction in insulin
concentration alongside an increase in blood glucose. Whereas the interaction between
glucose, insulin and vascular control remains to be elucidated fully, in the years
following the study conducted by Abramson and co-workers (36), it was established that
insulin-hypoglycemia is associated with an increase in skeletal muscle blood flow
(37,38).
In 1979 a technique was developed by DeFronzo and colleagues (39) known as
the euglycemic hyperinsulinemic clamp. This method involves the co-infusion of glucose
and insulin, such that, normal blood glucose concentration can be maintained in the
presence of hyperinuslinemia. The primary advantage of this model is that during insulin
administration, hypoglycemia as well as the negative side effects of hypoglycemia could
be avoided. From a vascular perspective, this enabled researchers to tease out the
differences between insulin-hypoglycemia, insulin-euglycemia, insulin-hyperglycemia
and glucose-stimulated insulin secretion on skeletal muscle blood flow control (40–49).
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Since the seminal work of Abramson and co-workers (36), the vasodilatory
effects of insulin have been studied extensively. Although many pathways may be
involved, it appears that insulin-stimulated vasodilation operates primarily through an
endothelium-dependent nitric oxide (NO) mechanism (50–52). This theory is based on
observations that insulin-stimulated increases in muscle blood flow are attenuated
dramatically when insulin and NO synthase inhibitors, L-NG-nitroarginine methyl ester
(L-NAME) or L-NG-monomethylarginine (L-NMMA), are co-infused (50,52). Likewise,
insulin-induced increases in skin blood flow are reduced when insulin and a NO synthase
inhibitor L-N-nitroarginine (L-NNA) or phosphatidylinositol 3-kinase (PI3-K) inhibitor
wortmannin are co-infused (53). In endothelial cells, NO synthase is activated by
intracellular enzymes PI3-K and protein kinase B (Akt) (54). Therefore, it has been
proposed that upon binding to the insulin-receptor, insulin activates intracellular
enzymes, PI3-K and Akt, which phosphorylate and activate endothelial NO synthase.
Endothelial NO synthase catalyzes the conversion of the substrate L-arginine to the
products L-citrulline and NO, and NO can diffuse into surrounding smooth muscle where
it stimulates vasorelaxation (51,54).

1.7

Glucose, insulin and the vasa nervorum

Based on the earlier results outlined above, the vascular etiology of diabetes
peripheral neuropathy emphasizes that hyperglycemia impairs microvascular function in
the nerve. This precedes and causes or exacerbates nerve dysfunction. Therefore, it is
essential to understand how acute and chronic hyperglycemia as well as insulinemia,
impact NBF control and nerve function. Unlike skeletal muscle (43,48), sciatic NBF is
reduced (55,56) following glucose infusion. This reduction in NBF may relate to gluco-
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inhibitory effects on adenosine-mediated vasodilation (56), NO synthase (57) or
increased NO scavenging as a result of the overt hyperglycemia (58,59). In contrast to
glucose, acute exposure to insulin stimulates vasa nervorum dilation (60). Why
hyperglycemia and the accompanying insulin secretion results in vasa nervorum
constriction, but insulin alone induces vasa nervorum dilation, is unknown. Regardless,
potentially, in the presence of acute hyperglycemia, insulin-mediated dilation is impaired.
Similar to the effects of acute hyperglycemia, untreated experimental diabetes or
chronic severe hyperglycemia is often associated with reduced NBF (7,55,61–63).
However, these findings are inconsistent, as others have documented no change (64,65)
or even increased (66–68) NBF following diabetes induction.
The physiological relevance of the untreated experimental diabetes model is
questionable, as that model results in excessive and sustained high blood glucose
concentrations (~25-40 mmol/L) (7,55,61). Compared with the degree of hyperglycemia
observed in humans with poorly controlled type 1 diabetes (~13.5 mmol/L) (4), the
experimental diabetes rodent model results in ~ ≥2-fold greater blood glucose
concentrations (7,55,61). Therefore, it is important to place an emphasis on the studies
that incorporate insulin treatment following diabetes induction. It has been established
that in rats with experimental diabetes, insulin treatment is beneficial to vasa nervorum
health (61,69–71). For example, insulin treatment administered from the onset of
hyperglycemia may prevent reductions in NBF, preserve vasa nervorum reactivity and
protect nerve function (69–71). Also, in rats with experimental diabetes, insulin treatment
may restore, at least partially, decrements in NBF and nerve function 1-month following
diabetes induction (61).
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Despite the advantages of insulin treatment, individuals with type 1 diabetes
continue to experience vascular and peripheral nerve dysfunction in the form of sensory
and motor nerve impairments (4,5,72). This may be the result of poor glycemic control or
impaired insulin signaling in the vasa nervorum of the peripheral nerve. To date the
effects of insulin-treated experimental diabetes on basal NBF and insulin responsiveness
in the vasa nervorum have yet to be elucidated. Such knowledge is critical for the
development of treatments to preserve vasa nervorum and nerve health in humans with
diabetes.
In addition to insulin treatment, researchers have investigated many
pharmacological strategies to improve vasa nervorum and nerve function in a rodent
model of diabetes (55,73–90). However, so far few studies have focused on the potential
benefits of exercise training. In humans (91) and in rats (92) with type 1 diabetes,
exercise training prevents or attenuates the progression of neuropathy. Whether exercise
training improves vasa nervorum function is unknown. As early as 1914, the diabetes
specialist E.P. Joslin prescribed repeated plantar flexion to improve circulation in the
lower limb (93). Later, he advocated regular physical activity in order to manage blood
glucose concentration and exogenous insulin requirement (94). Potentially, regular
exercise increases circulation and potentiates insulin signaling in the vasa nervorum
which would enhance overall nerve health.
In humans with type 1 diabetes, exercise may increase the risk of an adverse event
(i.e. hyperglycemia, hypoglycemia, musculoskeletal injury, cardiovascular incident,
deterioration of retinopathy and nephropathy); however, the benefits of exercise (reduced
glycosylated hemoglobin, increased life span, increased fitness, increased insulin
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sensitivity, increased sense of well-being and a reduced risk of cardiovascular disease,
colon cancer, hypertension, obesity and osteoporosis) outweigh the potential risks (95).
Therefore, it is essential to evaluate the role of exercise training in conjunction with
insulin treatment in the preservation of insulin signaling, vasa nervorum and nerve health.
The purpose of the projects described herein (Chapters 3, 4 & 5) was to examine
the effects of hyperglycemia on basal NBF as well as the potential vasodilatory effects of
insulin on NBF control in healthy rats and rats with insulin-treated experimental diabetes.
In addition, one project (Chapter 5) aimed to determine if exercise training enhances
insulin-mediated dilation in the vasa nervorum of rats with diabetes.
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Chapter 2

2

« Review of literature »
2.1

Sciatic nerve vasculature

The sciatic nerve is the largest peripheral nerve in the human body and contains
the largest arteria nervorum. Chief among the sciatic nerve feed arteries is the arteria
nervi ischiadi. It stems from the inferior gluteal artery and gives rise to 1-6 arterial
branches. The sciatic nerve also contains other smaller feed arteries that arise from the
femoral and popliteal arteries (1,2). The intraneurial circulation originates from the
aforementioned feed arteries at intervals along the sciatic nerve. Upon reaching the
sciatic nerve, the vessels bifurcate into ascending and descending branches that form an
intricate epineurial network of longitudinal arterioles. These arterioles can form arteriovenous anastomoses or branch into the nerve. The arterioles that branch into the nerve
traverse obliquely through the perineurium and form an endoneurial network within
nerve fascicles. The endoneruial network may contain arterio-venous anastomoses or
form a capillary plexus that drains into an emerging vein. Nerve vascular channels may
travel for a great distance along or within the nerve. Also, because capillary beds are
sometimes absent, some of these vessels are considered to be a continuous anastomotic
network (2). Various morphological approaches have been used to study the vasa
nervorum and include counting and sizing microvessels using light or electron
microscopy and a number of different perfusates (3–6). Radiographic and X-ray
microtomographic images of the vasa nervorum also exist and describe the sciatic nerve
vascular anatomy as well as the prospect of bidirectional flow (i.e. adjacent arteries
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traveling in opposite directions along the same segment of the nerve) in animal models
(2,7).

2.2
Sciatic nerve blood flow (NBF) measuring
techniques
The sciatic nerve vasa nervorum consists of an epi-, peri- and endoneurial
vasculature. Therefore, when assessing NBF it is important to consider what technique is
being used and whether the data represent gross flow or flow to specific portions of the
nerve. Numerous techniques have been developed and the methods used most commonly
are hydrogen clearance, microsphere distribution, laser Doppler flowometry and Doppler
ultrasound. The measurement of NBF is often invasive and requires sciatic nerve
exposure. The following discussion pertains to measuring sciatic NBF in an animal
model.
To assess NBF using the hydrogen clearance technique, hydrogen gas is added to
an inspired gas mixture. As the animal inspires the hydrogen gas, the hydrogen
concentration of the nerve is measured using a platinum electrode inserted into the sciatic
nerve endoneurium. When the hydrogen concentration of the nerve is stable, this
indicates equilibrium has been achieved between arterial and nerve hydrogen
concentration. Once equilibrium is reached, the hydrogen gas is removed and the
hydrogen clearance curve is measured until the concentration reaches pre-hydrogen
inspiration values (8,9). Using the rate of hydrogen clearance, blood flow values can be
calculated (8) and depending on the electrode placement, they are assumed to represent
endoneurial NBF (9,10).
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In addition to the hydrogen clearance technique, researchers often use the
microsphere tracer technique to assess NBF (11–16). Briefly, radio or fluorescent
labelled microspheres are infused into systemic circulation. Before and after the
microsphere infusion, reference blood samples are collected to determine the microsphere
concentration in arterial blood. At a designated time following the infusion, the sciatic
nerve is harvested and the labelled microsphere concentration from the reference blood
samples and the sciatic nerve (or specific portions of the nerve) can be used to calculate
NBF (12,15,17,18).
At approximately the same time as the microsphere distribution technique was
being developed, another method known as laser Doppler flowometry was being applied
to measure NBF (19–22). Unlike the aforementioned methods, laser Doppler flowometry
is an imaging technique that measures moving particles directly. To measure NBF, a
probe is placed superficially over the sciatic nerve and a light source emits a
monochromatic laser beam. Portions of the emitted light are absorbed by moving
particles, such as red blood cells, and the remaining backscattered light is detected by a
photo-detector. The frequency shift (i.e. the difference in the frequency of the emitted
beam vs the frequency distribution of the backscattered beam) is used to calculate net
flux (red blood cell number X velocity) and serves as a surrogate for NBF (19,23). Often,
researchers remove the epineurium so the net flux reflects peri- and endoneurial flow
exclusively (19,21,24).
Another advanced imaging technique being applied to measure NBF is Doppler
ultrasound (25). This method was employed to examine NBF in the present dissertation;
therefore, it is explained in detail here. The examination of NBF using Doppler
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ultrasound occurs in three stages; identification of the nerve using B-mode imaging,
location of the artery using power or colour Doppler and the measurement of NBF
velocity through a delimited segment of the selected artery using pulsed-wave Doppler
(25). Except where noted, the following theoretical descriptions of Doppler ultrasound
come from the book Medical Imaging Physics (26) and the methodological explanations
pertaining to the measurement of NBF were drawn from personal experience as well as a
previous study by Twynstra and colleagues (25).
To image the sciatic nerve, a transducer containing piezoelectric crystals is placed
superiorly to the dorsal aspect of the exposed sciatic nerve (coated with ultrasound gel).
An electric current is applied to the transducer and the piezoelectric crystals vibrate
resulting in the emission of mechanically produced high-frequency ultrasonic waves.
These sound waves penetrate the surrounding tissues and are reflected by tissues in
proportion to their density. The reflected sound waves are processed in terms of their
distance from the probe and combined to form a B-mode image. This two-dimensional
image is composed of bright dots representing the ultrasound echoes. The brightness of
each dot is determined by the amplitude of the reflected echo/sound wave. This imaging
technique is ideal for visualization and quantification of anatomical structures.
After the nerve has been identified the sciatic nerve vasculature is visualized
using colour Doppler. This approach requires the calculation of the Doppler shift (see
below) and provides a visual overview of flow within the nerve. Red blood cells moving
towards to the transducer will reflect sound waves at greater frequencies than the original
emitted frequency and be displayed in red. Conversely, red blood cells moving away
from the transducer will reflect sound waves at lower frequencies than the original
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emitted frequency and be displayed in blue. The intensity of the red and blue display
reflects the velocity of the moving particles.
The flow velocity waveform of the moving particles can be examined using
pulsed-wave Doppler. To achieve an optimal signal, the Doppler gate is positioned over
the site of the high-power colour Doppler signal. The Doppler shift will be calculated
from the sample volume demarcated by the gate. Briefly, following the identification of
the nerve, visualization of an artery and the selection of an arterial segment, the Doppler
shift and NBF velocity (NBV) data can be collected from a specific sciatic nerve arterial
site (Figure 2-1).

The following section will briefly discuss potential limitations regarding the use
of Doppler ultrasound (26). Red blood cell velocity is calculated as follows:
V = C (Fr - Fe) / (2Fe X Cosθ)

Figure 2.
2-11 Colour
Colour Doppler
Doppler screen
screen shot
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Where,
V = red blood cell velocity
C = the speed of sound in tissues (1540 m/s)
Fr = frequency of reflected sound waves
Fe = frequency of emitted sound wave
Cosθ = cosine of the angle of insonation
Consider that the speed of sound may vary in different tissues. However, such
differences are not taken into account in the calculation of blood flow velocity. Rather,
because the speed of sound in an average biological tissue is ~1540 m/s, this value is
assumed to be generally representative. Both the sciatic nerve and the vasa nervorum may
undergo structural changes as a result of ageing and prolonged diabetes, but whether this
or other experimental conditions impact the speed of an emitted or reflected ultrasonic
sound wave remains unknown.
In addition to its speed, the sound wave itself may also contribute to artifacts or
measurement error. For example, sound waves may be attenuated. This occurs when
sound waves are absorbed by surrounding tissues, the amplitude of the sound wave is
decreased and the reflected signal is dampened. Attenuation also occurs when sound
waves scatter. This is the diffusion or redirection of sound waves and occurs more often
when the wavelength of a sound wave is larger than the tissue being sampled. The highfrequency transducer used to measure NBF in the studies reported in this dissertation was
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operated at 32 MHz, which corresponds to a wavelength of 48 µm. In this case, because
the sound wave is ~5 times larger than a red blood cell (6-12 µm), scattering is likely to
occur. Attenuation (i.e. absorption and scattering) is an inherent limitation to Doppler
ultrasound imaging and little can be done to avoid it. However, because the sciatic nerve
vasa nervorum is relatively shallow (1-2 cm depth) and has a relatively low blood flow,
absorption and scattering are unlikely to be limiting factors in the measurement of NBV.
There are other components that contribute to artifacts in the blood flow velocity
signal, such as the angle of insonation, aliasing and motion artifacts, all of which can be
accounted for partially by adjusting the Doppler ultrasound parameters. Generally, the
ultrasound beam approaches the moving red blood cells at an angle (Doppler angle). This
reduces the frequency shift in proportion to the cosine of this angle. To minimize error
the preferred Doppler angle is ≤60o. At angles >60o the values for cosine θ change
rapidly and minor errors in angle accuracy can result in large errors in the measurement
of blood flow velocity (i.e. overestimating the angle of insonation produces a greater
magnitude of error than underestimating) (27). Also, if the ultrasound beam is
perpendicular to the direction of flow, the angle would be 90o and the cosine of 90o is
equal to zero (i.e. a Doppler shift would not be detected). Thus, the appropriate Doppler
angle is essential to obtain accurate measurements. To measure sciatic NBF in the studies
described herein (Chapters 3, 4 & 5), the transducer was secured in a bracket positioned
superiorly to the dorsal aspect of the sciatic nerve; the orientation of the transducer and
the angle of insonation could be adjusted accordingly to achieve an optimal signal
(Figure 2-1).
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After positioning the Doppler gate over the site of the high power colour Doppler
signal and achieving an appropriate Doppler angle, there are still other factors to
consider. Excessive Doppler shift frequencies may also contribute to errors in flow
velocity estimates. This phenomenon is known as aliasing and it occurs when the pulse
repetition frequency (i.e. number of emitted sound waves per second) is too low to assess
NBV accurately. The maximum Doppler shift or blood flow velocity that can be detected
is half of the pulse repetition frequency (Nyquist limit). Therefore, using pulsed-wave
Doppler, the pulse repetition frequency or sample rate may limit the estimation of flow
velocity. This occurs more frequently when examining deeper tissues, as the sample rate
will be limited by the time it takes for the sound to travel to and from the sample volume.
However, because the sciatic nerve and the vasa nervorum are exposed, tissue depth is
not an issue and an appropriate pulse repetition frequency can be selected.
The Doppler shift is calculated from the volume delimited by the Doppler gate or
sample volume. However, because the sciatic nerve artery is too small to resolve its
diameter quantitatively using B-mode or colour Doppler, it is possible that the sample
volume will contain both red blood cells and the arterial wall. The pulsatile movement of
the arterial wall may contribute to the spectrum of detected frequency shifts. To avoid
this, an adjustable wall filter is applied that discounts selectively low frequency
oscillations that occur at 40-50 Hz. Although this strategy will reduce spectral
broadening on account of eliminating smaller frequency shifts, because the outer
envelope of the mean blood flow velocity wave form is used when measuring NBV, the
overall impact of wall motion on estimates of NBV is likely minimal.
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It is important to note, that because the sciatic nerve arteries are too small to
resolve their diameters quantitatively using B-mode or colour Doppler, only velocity (not
flow) values can be obtained. Using 40 MHz technology, it has been demonstrated that
the smallest vessels that can be resolved are ~130 µm (28). Using the width of the power
Doppler signal, the basal diameter of a superficial sciatic nerve artery has been estimated
at ~70 µm. But because the resolution is limited to ~15 µm/pixel, changes in diameter
that do not exceed 20% of the total diameter cannot be detected (25). Also, at this
resolution changes in diameter can only be reported in 15 µm intervals. Limitations in the
ability to assess diameter and changes in diameter accurately using Doppler ultrasound
have resulted in values being reported in terms of velocity and not flow. This limits
general vascular interpretations and instead of using vascular conductance
(flow/pressure) researchers have been forced to use an index of vascular conductance
(flow velocity/pressure) to form inferences with regards to what is occurring in
downstream vascular beds (25).
Each of the aforementioned methodologies; hydrogen clearance, microsphere
distribution technique, laser Doppler and Doppler ultrasound, have advantages and
disadvantages. For example, to measure NBF using hydrogen clearance a paralytic agent
known as d-tubocurarie is administered to reduce limb movement and a platinum
electrode is inserted into the nerve which may potentially cause nerve as well as vasa
nervorum damage (9,10,29). Neuromuscular blocking agents and nerve exposure have
been investigated using the microsphere distribution technique and both conditions alter
NBF. However, NBF is altered differentially in control rats vs rats with diabetes. The
paralytic agent d-tubocurarie has no impact on NBF in control rats, but reduces NBF in
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rats with diabetes. Likewise, there is a hyperemic response to surgical trauma in control
rats, but this response is blunted in rats with diabetes (30). Conversely, limitations to the
microsphere technique are that insufficient microspheres may be captured to assess flow
accurately, dynamic changes in flow cannot be assessed and structural changes in the
vasa nervorum in rats with diabetes may enhance microsphere capture resulting in
increased NBF values artifactually (14,31,32). With regards to laser Doppler, it too
requires nerve exposure and sometimes removal of the epineurium which may alter NBF
values (19,21,33). In addition, because the sciatic nerve contains feed arteries arising
from different directions and arteries as well as veins with flow traveling in opposite
directions (2), laser Doppler measures of net flux are limited as they do not exclude
venous contributions to total flow. To examine NBF using Doppler ultrasound, the sciatic
nerve must also be exposed and only a segment of an artery can be investigated. Also, as
discussed because arterial diameter cannot be determined, Doppler ultrasound relies on
blood flow velocity and an index of vascular conductance (VCi=NBV/blood pressure) to
form inferences regarding downstream vascular control (25).
Divergent results between studies may be explained partially by differences in
measurement technique. However, some studies have incorporated two measurement
techniques, with each method arriving at the same conclusion (19). Conversely, other
studies have used the same technique and documented conflicting results (10,34). To date
no study has employed each method and validated or invalidated one or more techniques.
Also, the contribution of any single measurement technique or the error associated with
that technique to the overall outcome of a study remains unknown.

32

2.3

Autoregulation and basal NBF control

Under resting conditions organ blood flow tends to remain constant despite subtle
changes in perfusion pressure. This phenomenon known as autoregulation (35) was
documented in the early 1900s (36) and later described in detail by Rein in 1930 (37).
Maintaining relatively constant blood flow to organs such as the kidney, liver, heart,
brain facilitates nutrient exchange and the maintenance of capillary pressure which is
important for fluid balance. In the 1960s five mechanisms/components were considered
to contribute to autoregulation: 1) metabolic, 2) tissue pressure, 3) myogenic, 4) tubuloglomerular feedback from the kidney and 5) neural. Since then it is generally accepted
that these mechanisms may operate together or independently in a tissue-specific manner
to maintain tissue perfusion (35).
Unlike other tissues in the body sciatic NBF is not autoregulated. Instead, blood
flow in the vasa nervorum responds passively to changes in arterial blood pressure
(9,20,21,38,39). Using the hydrogen clearance method to measure NBF, Smith and coworkers (39) documented simultaneous reductions in blood pressure and NBF during
exsanguination. In this study NBF values also increased at blood pressures between 80110 mmHg. However, angiotensin-induced increases in blood pressure beyond 110
mmHg did not augment NBF further. It was speculated that NBF did not increase at
blood pressures greater than 110 mmHg because of the vasoconstrictor effect of
angiotensin. Thus, to avoid confounding effects of a vasoconstrictor, Low & Tuck (9)
used the same measurement technique, but instead of a drug infusion they connected an
arterial cannula to a reservoir (filled with heparinized saline or citrated rat whole blood)
and adjusted the height of the reservoir to obtain hydrostatic pressures equivalent to 60-
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160 mmHg (above the heart level). They documented a curvilinear relationship
(convexity towards the abscissa) between NBF (y-axis) and blood pressure (x-axis) up to
pressures of ~160 mmHg. Similar observations have been made using laser Doppler
flowometry (20,21); however, these studies report a linear relationship between NBF and
blood pressure between pressures of ~25-150 mmHg.
It is unclear why peripheral nerves do not have autoregulated NBF. Potentially,
nerves do not rely on acute fluctuations in blood flow to meet changing metabolic
requirements (40). Peripheral nerves are particularly resistant to ischemia (41,42) and
NBF does not increase during hypoxia (9). Although sciatic NBF does increase modestly
in response to nerve stimulation (16,43), the energy expenditure of nerves and the
increase in NBF following stimulation is relatively low (16,41). Further, the peripheral
nerve and vasa nervorum receive cholinergic input and express muscarinic receptors (44–
47). Therefore, it is possible that nerve stimulation and neural transmission elicit an
acetylcholine-induced, muscarinic receptor-dependent, NO-mediated vasa nervorum
dilation (29,48).
The absence of autoregulation in the vasa nervorum is a hallmark feature of NBF
control, but its significance remains unclear. Kihara and co-workers (40) documented that
the relationship between blood pressure and NBF changes with age, such that during
periods of growth NBF is greater for a given blood pressure. This may be explained by a
relatively elevated metabolic demand or increased ‘vascular volume:nerve tissue’ ratio
during such developmental stages (41). Despite these observations, the lack of
autoregulatory control persists throughout the life span (40). Since these initial
observations few studies have extended upon the general understanding of (non-)
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autoregulatory sciatic NBF control (38,49). Instead, during this time period much of the
vasa nervorum research has focused on the impact of diabetes and insulin treatment on
basal NBF and vasa nervorum reactivity. How diabetes impacts the pressure-flow
relationship in the vasa nervorum has not been studied extensively, but understanding this
phenomena and how it is impacted by disease may help explain conflicting results
between studies (i.e. it has been documented that experimental diabetes may decrease,
increase or have no effect on basal NBF) (10,12–14,32,34,49–51), as well as clarify the
link between hypertension and diabetes peripheral neuropathy (52).

2.4
Acute effects of glucose and insulin on NBF
control
To test the effects of acute hyperglycemia on NBF, Cameron and colleagues (32)
infused glucose intravenously until blood glucose concentrations reached values observed
in untreated experimental diabetes (>30 mmol/L). Using the hydrogen clearance
technique they measured NBF at baseline, peak glucose concentrations (>30 mmol/L)
and in recovery. They documented ~50% reduction in NBF that corresponded to an
increase in vascular resistance by ~180%. They also noted that, as blood glucose
concentrations returned closer to baseline values, NBF and vascular resistance were
gradually restored (32). In a similar study, using laser Doppler, Saini and co-workers
(53) documented reductions in NBF following glucose infusion performed intravenously
or through an intra-peritoneal injection. The peak glucose concentration obtained was
~10 mmol/L. Based on these findings, it appears only a modest level of hyperglycemia
must be achieved to reduce NBF. In this study (53) the effect of glucose to reduce NBF
was abolished by co-infusion with adenosine. Further, the restoration of NBF by
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adenosine was abolished by co-infusion with theophylline (a non-selective adenosine
receptor antagonist). Therefore, Saini and colleagues (53) concluded that acute
hyperglycemia reduces NBF through an inhibitory effect on vasa nervorum adenosine
receptors. Whereas the effects of adenosine on NBF have not been studied extensively, in
the coronary vasculature it is generally accepted that adenosine receptors mediate NO
release from the endothelium as well as smooth muscle hyperpolarization (54). In line
with the aforementioned observations regarding NBF, acute hyperglycemia is also
associated with impaired vascular function as a result of reduced NO functioning (55,56).
In vitro, endothelial cell exposure to incremental hyperglycemia is associated with a
progressive decline in NO availability (57) and NO-mediated vascular relaxation (58).
Further, the impact of imapired NO function may extend beyond the immediate reduction
in vasodilatory capacity and expose the vasa nervorum to the vasoconstrictor effect of
other compounds, such as endothelin or norepinephrine (59–61). Therefore, reductions in
NBF during acute hyperglycemia may be explained by a direct effect on adenosine
receptor blockade, enhanced NO scavenging, impaired NO function and decreased
smooth muscle cell hyperpolarization, as well as indirect effects of impaired dilatory
capacity rendering the vasa nervorum more susceptible to vasoconstrictor influences.
The effects of glucose infusion on blood flow control may be different between
the vasa nervorum and skeletal muscle vasculature. Specifically, acute rises in blood
glucose appear to mediate a vasa nervorum constriction, but stimulate skeletal muscle
vasodilation (62,63). Despite dissimilar responses to acute glucose administration, insulin
stimulates vasodilation in both vascular beds (64–69). In skeletal muscle insulin-
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mediated dilation is NO-dependent (65,68). Whether the same is true for the vasa
nervorum remains unclear (69).
Acute and chronic hyperglycemia and potentially hypoinsulinemia impair NBF
and nerve function (50,53,70,71). The vascular responses to glucose and insulin are
fundamental to the etiology of diabetes peripheral neuropathy (10,13,14,50,72).
Exploring how glucose and insulin interact to modulate NBF and nerve function is
necessary to gain an understanding of the pathology and potential treatment of diabetes
peripheral neuropathy.

2.5

Effects of untreated experimental diabetes on NBF

Untreated experimental diabetes has been associated with greater (12–14), normal
(22,34,73) as well as reduced resting NBF (10,32,49–51, 73). It is uncertain why such
discrepancies exist, as conflicting results have been obtained using the same
measurement technique (10,34) as well as similar models of untreated experimental
diabetes (i.e. male Sprague-Dawley rats, STZ dose=45-60 mg/kg, diabetes duration= 4-6
weeks) (13,32,34). Following the induction of experimental diabetes, it is possible the
presence (49) or absence (4) of sciatic nerve microangiopathy may account for dissimilar
NBF values. However, from a metabolic stand-point it can be argued that the metabolicmilieu associated with experimental diabetes may increase, decrease or have no effect on
resting NBF. A review of this topic can be found elsewhere (74).
Evidence to suggest experimental diabetes is associated with increased NBF
comes largely from Williamson and colleagues (12–14) and relies on the microsphere
distribution technique (discussed earlier). They speculated that diabetes-induced
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elevations in NBF are caused by increased cytosolic reductive stress (14). Briefly,
hyperglycemia results in increased sciatic nerve glucose uptake. Excess glucose in the
nerve is reduced to sorbitol coupled with the oxidation of cofactor NADPH-to-NADP+
by the enzyme aldose reductase. Thereafter, sorbitol is oxidized to fructose coupled with
the reduction of NAD+ to NADH by the enzyme sorbitol dehydrogenase. Thus, increased
glucose metabolism through the sorbitol pathway results in increased formation of
NADH (12,14,75). It has been postulated that the accumulation of NADH causes
cytosolic reductive stress and may result in vasodilation through two primary
mechanisms. Firstly, because this metabolic state (elevated NADH-to-NAD ratio)
resembles the biochemical changes that result from hypoxia it may result in increased
blood flow (75,76). However, Low and Tuck (9) documented previously that NBF does
not autoregulate or respond to hypoxia; thus, the pseudo-hypoxic state caused by the
cytosolic reductive stress is unlikely to modulate NBF control. The second proposed
mechanism of vasodilation argues that reductive stress may result in an increase
intracellular calcium concentration which could activate NO synthase. In addition, that
elevated protein kinase C activation (which occurs as a result of hyperglycemia) (58) may
contribute to the phosphorylation of endothelial NO synthase (75,77). However, this
proposed mechanism is also controversial because both NO synthase and sorbitol
synthesis rely on the oxidation of the cofactor NADPH and excess glucose metabolism
may deplete NADPH stores resulting in decreased NO production (78).
In contrast to reports of elevated NBF, the evidence supporting the link between
diabetes and reduced NBF implicate limited NO availability, but also many other factors.
In endothelial cells hyperglycemia or elevated intracellular glucose metabolism may
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increase reductive stress/pseudo-hypoxia (as described above), stimulate de novo
diacylglycerol synthesis and subsequent protein kinase C activation, and result in the
formation of advanced glycosylation end-products. These pathways are interrelated and
the cumulative effect of chronic hyperglycemia may be reduced NO synthase activity,
increased endothelin-1 activity, increased oxidative stress and microangiopathy (79).
To elucidate how exactly chronic hyperglycemia reduces NBF, many studies have
focused on placebo-controlled pharmacological interventions. For example, the following
is a list of pharmacological targets used to prevent diabetes-induced impairments in NBF:
α1-receptor antagonists (prazocin, doxazocin) (3,80), β2-agonist (salbutamol) (81),
catecholamine release inhibitor (guanethidine) (32), Ca+ channel antagonist (nifedipine)
(82,83), prostacyclin analogue (beraprost) (84,85), endothelin receptor antagonist
(bosentan) (86), endothelin-1a receptor antagonist, angiotensin II receptor antagonist
(87), aldose reductase inhibitor (88–90), protein kinase C-β selective inhibitor (91),
advanced glycated end-product inhibitor (aminoguanidine) (92), angiotensin converting
enzyme inhibitor (cilazapril), NO donor treatment (isosorbide dinitrite) (93) and various
compounds involved with lipid metabolism (94–96). Despite the wide variety of targets,
many of the aforementioned treatments interact with and may enhance NO production or
availability (81,92–95,97,98). Diabetes-induced oxidative stress may attenuate NBF
through impaired NO synthesis or availability and because oxidative stress is multifactorial, any treatment that attenuates oxidative stress may have downstream effects on
NO signaling in the vasa nervorum.
Regarding the effects of experimental diabetes on NBF control, recall that acute
hyperglycemia may also impair NBF (32,53). If blood glucose was not normalized before
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the NBF measurements were performed it would be impossible to discern between the
acute and chronic effects of hyperglycemia. Therefore it may have been concluded
inappropriately that the effects of diabetes were caused exclusively by chronic
hyperglycemia, because the effects of acute hyperglycemia were not considered.
An attenuated or dysfunctional vasodilatory influence (i.e. impaired NO
signaling) is the primary explanation for diabetes-related impairments in NBF. However,
there is also the possibility of an enhanced vasoconstrictor influence. Topical application
of adrenergic agonists, norepinephrine (non-selective α adrenergic agonist) and
phenylephrine (α-1 adrenergic agonist), constrict the vasa nervorum in a dose-dependent
manner (60,99). Whereas diabetes does not appear to enhance the constrictor response to
phenylephrine (83), it does augment vasa nervorum responsiveness to exogenous (topical
application) norepinephrine (61). However, in the aforementioned study enhanced
responsiveness to norepinephrine was explained partially by defective endothelial NO
signaling. Therefore, reductions in NBF following diabetes induction may reflect an
interaction and imbalance between multiple vasodilator and vasoconstrictor influences.
The potency and wide-spread damage of uncontrolled hyperglycemia may help explain
the diversity of causes as well as successful treatments associated with diabetes-related
decrements in NBF.

2.6

Insulin treatment and NBF

Whereas untreated experimental diabetes highlights the pronounced effects of
chronic hyperglycemia, the physiological relevance of this model is questionable because
the blood glucose values are ~ ≥2-fold greater (10,32,50) than values observed commonly
in humans with poorly controlled diabetes (100). Therefore, it is essential to consider
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those studies that include insulin treatment when evaluating how type 1 diabetes might
impact NBF control. The sciatic nerve vasa nervorum contains insulin receptors (101),
supporting the notion that insulin treatment may alter the pathophysiology of diabetesinduced vasa nervorum and nerve dysfunction. Insulin treatment initiated at the onset
(71,102) or one month following the induction of experimental diabetes (50) attenuates
diabetes-induced decrements in NBF. Insulin treatment also reduces blood glucose and
by extension reduces glucose flux in the nerve (102). Reduced hyperglycemia and sciatic
nerve glucose metabolism may result in less oxidative stress and therefore, attenuate NO
scavenging. Accordingly, insulin treatment preserves vasa nervorum reactivity likely
through a NO synthase mechanism (29) and possibly through increased sciatic nerve
cyclic AMP content (102).
Acute and chronic exposure to insulin increases NBF (50,102,103), potentially
through a NO mechanism (29,65,69,104). Though insulin does act as a vasodilator in the
vasa nervorum (69), the dilatory properties of insulin may be enhanced by the
simultaneous reduction in hyperglycemia associated with increasing insulin
concentrations. To date, the independent contributions of glucose stimulated insulin
secretion, hyperglycemia and hyperinsulinemia on NBF control are unknown.
Insulin remains the most successful and widely used treatment for type 1 diabetes.
However, insulin treatment alone may be insufficient to protect individuals with type 1
diabetes from an elevated risk of developing vascular disease and nerve dysfunction
(52,105). Combining insulin with drugs such as angiotensin converting enzyme
inhibitors, statins and protein kinase C inhibitors has been used to treat complications
associated with diabetes. These treatments are highly specific, may have negative side
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effects and do not work in all individuals (105). This highlights a need to develop more
effective treatment strategies for individuals with diabetes and in particular those with
poorly controlled blood glucose, who are at a greater risk of developing diabetes-related
complications.

2.7

Exercise and NBF

Prior to the discovery of insulin, Dr. E.P. Joslin prescribed repeated plantar
flexion exercise to increase lower limb circulation in patients with type 1 diabetes (106).
Following the discovery of insulin, he advocated regular exercise to help moderate blood
glucose concentration and exogenous insulin requirements (107). More recently, it has
been established that regular exercise may help avoid or attenuate the progression of
nerve dysfunction in patients with type 1 diabetes (108) by preserving nerve fiber density,
integrity and myelination (109). However, how exercise training impacts vasa nervorum
function is not clear. Acute exercise improves nerve function in non-neuropathic patients
with type 1 diabetes and it is believed that such improvements may be due to acute
exercise-induced rises in NBF. Indeed, acute electrical nerve stimulation and skeletal
muscle contraction increase NBF (16,43) and the vasodilation response to electrical
stimulation remains intact in rats with type 1 diabetes. Whether repeated nerve
stimulation and skeletal muscle contraction in the form of exercise training has the same
effect (vasa nervorum dilation), or whether repeated increases in NBF improves vasa
nervorum reactivity has not been studied. Exercise training improves brachial artery
flow-mediated vasodilation (an indicator of endothelial function) in patients with type 1
diabetes (110). Likewise, regular exercise enhances insulin-mediated vasodilation in the
skeletal muscle (111,112) and cutaneous tissue microvasculature (113) in control rats and
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rats with type 2 and type 1 diabetes, respectively. Relative to type 1 diabetes, exercise
training-induced increases in microvascular reactivity to insulin are attenuated with
simultaneous infusion of PI3-K inhibitor wormannin or NO synthase inhibitor L-NNA
(113). Based on these data, it appears exercise training potentiates insulin-mediated
vasodilation through the activation of intracellular enzymes PI3-K and Akt, which
phosphorylate and activate eNOS. The aforementioned experimental observations
support Dr. E.P. Joslin’s thesis that acute exercise improves lower limb circulation (106)
and regular exercise potentiates the effects of insulin (indicated by a reduced need for
exogenous insulin in individuals with type 1 diabetes who exercise regularly) (107).
Theoretically, exercise training enhances microvascular responses to insulin in the vasa
nervorum and improvements in microvascular function mediate improvements in nerve
health.

2.8

Perspectives

Since the mid-1700s the potential significance of the vasa nervorum as it pertains
to nerve function or dysfunction has been under examination (114). Whereas many of the
early studies focused on the effects of nerve compression and vascular occlusion/ligation
(115–119), the focus shifted over the next 50 years with the discovery of insulin
treatment in the 1920s. As the life expectancy for humans with diabetes increased; on
account of their vulnerability to peripheral nerve complications, questions regarding the
impact of diabetes on vasa nervorum and nerve health emerged. Beginning in the 1950s
and continuing today, an emphasis has been placed on the pathophysiology of diabetesinduced vascular disease in the vasa nervorum, as well as how such factors may
contribute to overall nerve health (10,49,72,120–123). Despite the general success of
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insulin treatment, individuals with type 1 diabetes are still exposed to a greater risk of
developing vascular disease and diabetic peripheral neuropathy (52,105). This may occur
as individuals with type 1 diabetes often experience moderate hyperglycemia (100),
which impairs vascular function directly (53,58,79,124) as well as affecting insulin
signaling adversely in both the vasa nervorum and the nerve (125–127). Thus, the
benefits of insulin treatment on vascular health may be offset partially by poor glycemic
control.
Whether poor glycemic control alters nerve function through a NBF mechanism is
difficult to discern. Using a rodent model for type 1 diabetes nerve dysfunction has
occurred alongside no change (34) increased (13,14) or decreased (10,32) NBF. Based on
these observations, baseline NBF may not be a critical factor in the development of
diabetes peripheral neuropathy, or the vascular etiology of diabetes peripheral neuropathy
may change depending on the NBF status. Insulin treatment may attenuate or abolish
diabetes-related alterations in NBF and nerve function (29,50,71). But insulin treatment
alone is often insufficient and other treatments are often combined with insulin to help
treat diabetes-related complications (50,105). That insulin treatment alone is often
insufficient suggests insulin signaling in the vasa nervorum or the peripheral nerve is
impaired by poor glycemic control. Also, that interventions focused on improving insulin
signaling instead of inhibiting downstream targets of hyperglycemia may be more
suitable to improve overall vascular and neuronal health outcomes (70,128,129). Unlike
many pharmacological interventions, exercise training serves as an attractive intervention
as it improves many aspects human health (130) including insulin sensitivity (131–133),
vascular (110,134) and neuronal health in populations with type 1 diabetes (108,109). To
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date, the effect of exercise training on insulin signaling in the vasa nervorum and vasa
nervorum reactivity remains unknown. Potentially, the benefits of exercise training on
nerve health are mediated in part by improvements in vasa nervorum insulin
responsiveness.

2.9

Purpose and hypotheses

The purpose of the studies described herein (Chapters 3, 4 & 5) were to
investigate the effects of acute and chronic hyperglycemia on basal NBF, as well as the
vasoactive effects of insulin on NBF control in healthy rats and rats with insulin-treated
experimental diabetes. Further, one study (Chapter 5) sought to determine if exercise
training could prevent diabetes-induced declines in vasa nervorum function. These
objectives were divided into three separate projects, with the following purposes and
hypotheses:
1. Purpose: To determine the effects of insulin-treated experimental diabetes on
basal NBF and assess NBF across a range of arterial blood pressures (i.e. examine
the impact of diabetes in the absence of autoregulation).
a. It was hypothesized that insulin-treated experimental diabetes would
reduce NBF modestly and attenuate the NBF response to dynamic changes
in blood pressure.
2. Purpose: To assess to vasoactive effects of glucose and insulin on NBF control in
a healthy state.
a. It was hypothesized that glucose infusion and the subsequent
hyperglycemia would reduce NBF. However, insulin infusion would
increase NBF.
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3. Purpose: To examine the effects of insulin-treated experimental diabetes with and
without endurance exercise training on vasa nervorum responsiveness to insulin.
a. It was hypothesized that insulin-treated experimental diabetes would
reduce vasa nervorum reactivity to insulin, but deficits in vasoreactivity
would be prevented by concurrent endurance exercise training.
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Chapter 3

3

« The relationship between blood pressure and sciatic
nerve blood flow velocity in rats with insulin-treated
experimental diabetes»
3.1

Introduction

The etiology of diabetic peripheral neuropathy (DPN) may be explained partially
by declining peripheral vascular function (1). In rats with experimental diabetes, deficits
in motor nerve conduction velocity (MNCV) are often linked with reduced basal nerve
blood flow (NBF) (2–6). The mechanism responsible for reducing NBF is multifactorial
and may include abnormalities in autonomic function, calcium handling, endothelial
function, lipid/glucose metabolism or the renin-angiotensin system [for review see (7)].
Reduced NBF is believed to contribute to neural ischemia resulting in nerve dysfunction
and DPN (1–3). However, decrements in NBF do not always precede DPN (8–10).
Indeed, some authors have documented no change (8) or increased (9,11,12) NBF
following diabetes induction. The relationship between basal NBF and nerve function
remains to be elucidated fully. However, it appears diabetes-induced nerve dysfunction
may occur independently of reduced NBF.
Hypertension is an independent risk factor for DPN (13). Theoretically, because
NBF does not autoregulate, but instead responds passively to changes in blood pressure
(14–19), elevated blood pressure should result in augmented NBF. However, Gregory
and co-workers (6) documented that rats with diabetes had reduced NBF in the presence
of normal and elevated blood pressure. Likewise, rats with diabetes presented with
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peripheral nerve microangiopathy. Based on these data, it appears the non-autoregulatory
relationship between blood pressure and NBF is altered in a diabetic state.
In a recent study, patients with poorly controlled type1 diabetes presented with
~9% glycosylated hemoglobin values (20). This corresponds to a blood glucose
concentration of ~13.5 mmol/L (21) and contrasts with values obtained during
experimental diabetes (blood glucose=27-43 mmol/L) (2,3,4) emphasizing the problem
that chronic, severe hyperglycemia may not reflect a moderately hyperglycemic insulintreated, type 1 diabetes state. In rats with experimental diabetes, insulin treatment
partially restores resting NBF (4,22), improves vasa nervorum reactivity (23) and
enhances nerve function (4,24–26). However, whether insulin treatment impacts
microangiopathy remains unclear (26–28) and if it alters the relationship between blood
pressure and NBF is unknown.
The purpose of this study was to examine the effect of chronic, moderate
hyperglycemia (i.e. more clinically relevant blood glucose concentrations) on the
relationship between blood pressure and NBF. We tested the hypothesis that moderately
hyperglycemic insulin-treated experimental diabetes (DS) would reduce basal sciatic
NBF and also alter the non-autoregulatory relationship such that NBF would be reduced
across a range of mean arterial pressures (MAP).

3.2

Methods

Moderately hyperglycemic rat model( 29)
Eight-week-old male Sprague-Dawley rats (Charles River Laboratories; SaintConstant, Quebec, CA) were injected with 20 mg/kg streptozotocin (STZ; Sigma-
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Aldrich, St. Louis, MO, USA; citrate buffer pH 4.5) over five consecutive days. Postconfirmation of two blood glucose readings >18mmol/L, rats received a surgically
implanted subcutaneous insulin pellet (Linplant, Linshin, Toronto, ON, CAN; release rate
1 IU/12 h; one pellet per 150 g mass and one pellet for each additional 100 g). To
maintain moderate hyperglycemia and replicate blood glucose values observed in humans
with poorly controlled type 1 diabetes (20), blood glucose was monitored daily during the
first week of insulin therapy and weekly thereafter, and pellet size was adjusted
accordingly (see table 3-1 in the results section). Experimental testing occurred at 10
weeks post-implantation of the first insulin pellet.
Experimental design
All procedures complied with the Animal Care guidelines and ethics approval
board from The University of Western Ontario. Rats were housed in pairs at a constant
temperature of 20±1oC with a 12-hour light/dark cycle and had ad libitum access to
commercial chow (PROLAB RMH 3000, Brentwood, MO, USA) and water. Rats were
divided randomly into two groups; control (n=8, mass=560±31 g) and DS (n=9,
mass=456±33 g). Saphenous vein blood samples were collected weekly during the fedstate, and blood glucose was measured (data presented as average blood glucose
throughout the study). At the end of the 10th week, blood pressure in the conscious animal
was measured. Subsequently, under anesthesia, nerve arterial vasomotor control and
MNCV were assessed. Thereafter, sciatic nerves were harvested for histological analyses.
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Conscious blood pressure testing (control, n=7; DS, n=9)
Mean, systolic and diastolic blood pressure (SBP; DBP) as well as heart rate were
measured using the tail-cuff method (CODA; Kent Scientific CO. Torrington, CT. USA)
in conscious rats. Prior to data collection, all rats were familiarized with the CODA
system on multiple occasions.
Surgical procedures
Rats inhaled isoflurane gas (4%) and received an intra-peritoneal injection of
urethane (25 mg/kg) and α-chloralose (4 mg/kg) prior to the onset of surgery. After ~20
min, the gas was removed and the urethane α-chloralose mixture alone maintained
surgical depth. A warming blanket was used to maintain rat body temperature at 37oC
(rectal probe). A catheter inserted into the right jugular vein facilitated all anaesthetic
and drug infusions. A catheter inserted into the right carotid artery was connected to a
pressure transducer (PX272, Edwards Lifesciences, Irvine, CA, USA), and enabled
continuous blood pressure recordings. Thereafter, the left sciatic nerve was exposed via
blunt dissection (30).
Nerve blood flow velocity protocol (control, n=6; DS, n=6)
After surgery, following 1 h of stabilization, MAP and nerve blood flow velocity
(NBV; Vevo 2100 ultrasound system VisualSonics, Toronto, ON, CA) were measured at
baseline 1 (pre-sodium nitroprusside; SNP; NO donor), during SNP (60 µg/kg, 110
µg/mL) infusion (early and late), baseline 2 (pre-phenylephrine; PE; α1 adrenergic
agonist) and during PE (12 µg/kg, 10 µg/mL) infusion (early and late).
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Vascular conductance and estimated conscious nerve blood flow velocity
Sciatic NBV and MAP values were used to calculate the index of vascular
conductance (VCi= BV/MAP). Sciatic NBV was plotted as a function of MAP for the
time points: baseline 1, baseline 2, SNPearly, SNPlate, PEearly and PElate; and
regression equations for each animal were created, averaged and plotted separately for
each group. Conscious MAP values were substituted into the appropriate individual
regression equations to estimate conscious NBV values for each rodent, in both groups.
Motor nerve conduction velocity protocol (control, n=7; DS, n=6)
Following the pharmacological intervention, MNCV was determined in the
sciatic-tibial nerve. The left sciatic nerve was stimulated first at the sciatic notch, and
then at the popliteal fossa. Using a constant-voltage clinical electrical stimulator
(NeuroscanComperio, Compumedics Medical Systems, El Paso, TX, USA), nerve
stimulation consisted of a series of single 100 µs, supramaximal pulses delivered through
a bipolar stimulating electrode that was held over the exposed nerve. Supramaximal
stimulation was achieved at ~20 mA. The evoked compound muscle action potentials
(CMAP) were recorded from the tibialis anterior muscle using intramuscular, tungsten
recording electrodes inserted into the muscle.
Sciatic nerve harvesting (control, n=6; DS, n=6)
After the MNCV experiment, rats were euthanized and their sciatic nerves were
harvested, fixed in 4% paraformaldehyde for 72 h and embedded in paraffin blocks for
histological analysis. Tissue blocks were sectioned transversely 8 µm thick, mounted on
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positively charged slides (VWR Suprafrost Plus; Batavia, IL, USA) and stained with a
routine hematoxylin (H) & eosin (E) protocol. The H&E stain was used to expose blood
vessels and quantify total sciatic nerve fascicular blood vessel number (31).
Data acquisition and analysis
The analog blood pressure signal sampling occurred at 1000 Hz (Powerlab;
ADInstruments, Colorado Springs, CO, USA). Pulsatile blood pressure over 5 beats
(corresponding to the same 5 NBV waveforms) was averaged to calculate MAP.
NBV was measured using Doppler ultrasound and a 40 MHz linear array probe
(MS550D) transducer placed over an artery lying superficially along the sciatic nerve.
Power Doppler was used to locate the superficial nerve artery. This arterial segment was
studied using the duplex imaging mode (frequency of 32 MHz with 100% power, PRF
between 4-5kHz and wall filter of 40-50Hz) with the pulsed wave Doppler gate (~0.12
mm width) positioned over the site of the high power Doppler signal (insonation angle of
60°). This ultrasound system did not have sufficient resolution to measure changes in the
sciatic nerve supply artery diameter in B-mode images. Thus, peak NBV (outer envelope
of the flow-velocity waveform) represents a surrogate for NBF rate.
Compound muscle action potentials were displayed and stored on a digital
electromyography (EMG) acquisition system (NeuroscanComperio, Compumedics
Medical Systems, El Paso, TX, USA). Electromyography signals were sampled at 10 kHz
and band-pass filtered at 10 Hz to 10 kHz. Motor nerve conduction velocity was
calculated by subtracting the distal from the proximal latency (measured in milliseconds)
from the stimulus artifact of the initial inflection of the evoked CMAP waveforms, and
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the difference was divided into the distance between the two stimulation sites (measured
in mm). The MNCV was reported in m/s.
The number of nerve blood vessels in the largest fascicle was counted
independently by two observers blinded to the experimental condition. Images were taken
on an Axiovert S100 brightfield microscope at 40X magnification, using Northern
Eclipse imaging software (EMPIX Imaging Inc.; Mississauga, ON, CAN). To determine
the total vessel count, the nerve fascicle of interest was sectioned into quadrants visually.
The aggregate of each quadrant represented the total vessel count for the individual nerve
fascicle. The measurements from the two observers were averaged for each nerve and
the average value was used for analysis. The nerve fascicle area and blood vessel
diameters were measured using image J software (http://imagej.nih.gov/ij/).
Statistics
Independent two-tailed t-tests were used to test the effect of group (control vs DS)
for the animal characteristics (Table 3-1). A mixed model ANOVA assessed the effect of
group and time on MAP, NBV (Table 3-2) and VCi during the study phases which
included in sequence baseline 1, SNPearly, SNPlate, baseline 2, PEearly and PElate time
periods (Sigma Stat for Windows, version 8.0). The same analysis was completed on the
∆MAP and ∆NBV response to SNP and PE infusions (Figures 3-1 & 3-2). For each
animal, NBV vs MAP was plotted and the slope and y-intercept values were averaged for
each group. Independent two-tailed t-tests were used to test the effect of group (control
vs DS) on the average slope and y-intercept values (Figure 3-4), as well as for MNCV
(Table 3-1) and the number of sciatic nerve fascicle blood vessels (Table 3-3). Lastly, an
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independent two-tailed t-test was used to test the effect of group (control vs DS) on
estimated NBV in the conscious rat (Figure 3-4). The significance level was set at
P<0.05 and data are presented as mean±SD.

3.3

Results

General characteristics
Relative to the control group, body mass was reduced (Table 3-1; P<0.01), and
fasting and fed state blood glucose concentrations were greater (Table 3-1; P<0.01) in the
DS group. There were no differences in conscious heart rate between groups (Table 3-1;
P=0.85). Compared with control rats, systolic, diastolic and MAP in the conscious state
were greater (Table 3-1; P<0.01), while MNCV was reduced (Table 3-1; P<0.01) in the
DS group.
Mean arterial pressure and nerve blood flow velocity
In the anesthetized state, no group or interaction effects were observed for MAP
or NBV (P≥0.16). A main effect of time was observed for MAP and NBV (P<0.01).
Subsequent pairwise comparisons indicated that baseline 1 and 2 were similar (P≥0.60),
relative to baseline 1, SNP reduced MAP and NBV (P<0.01) and relative to baseline 2,
PE increased MAP and NBV (P<0.01). Group data for MAP and NBV can be located in
Table 3-2.
No group or interaction effects were observed for VCi (P≥0.47). A main effect of
time was observed for VCi (P<0.01), where all time points were significantly greater than
SNPlate (P<0.01; data not shown).
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No group or interaction effects were observed for ∆MAP and ∆NBV (P≥0.20). A
main effect of time was observed for ∆MAP and ∆NBV (P<0.01). Subsequent pairwise
comparisons indicated that ∆MAP and ∆NBV measured during SNPlate were greater
than SNPearly (P<0.01) and those measured during PElate were greater than PEearly
(P<0.01). Group data for ∆MAP and ∆NBV can be located in Figures 3-1 & 3-2
respectively.
Regression equation and estimated conscious nerve blood flow velocity
The average slope of the regression between MAP and NBV (control=1.03±0.16
vs DS=0.99±0.27; P=0.77), and the corresponding y-intercept (control= -19.28±9.15 vs
DS= -19.45±19.83; P=0.99), were similar between groups (Figure 3-3). Estimated NBV
for a conscious rat was significantly (P=0.02) greater in the DS group (Figure 3-4).
Blood vessel counting
The total number of vessels as well as the total area and number of vessels/mm2
were similar (P≥0.73; Table 3-3) between groups (Figure 3-5). There appeared to be two
sizes of blood vessels with one or three layers of smooth muscle. The proportion of
smaller (~70%) and larger (~30%) blood vessels were similar (P≥0.68) between groups.
The estimated radius of the larger blood vessels was similar between groups (P=0.50).
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Table 3-1 Animal Characteristics
Measures

Control (n=7-8)

DS (n=6-9)

Mass (g)

560±31

456±33*

Fed state blood glucose (mmol/L)

4.4±0.2

14.1±1.2*

Fasting blood glucose (mmol/L)

3.6±0.2

7.0±2.7*

NA

6.0±2.4

Conscious heart rate (bpm)

417±33

421±26

Conscious SBP (mmHg)

149±13

171±8*

Conscious DBP (mmHg)

99±19

124±10*

Conscious MAP (mmHg)

115±17

139±8*

MNCV (m/s)

56.9±5.6

43.1±5.3*

Insulin Dose (IU/kg/day)

*, Significantly different than control (P<0.05)
DS: insulin-treated experimental diabetes
SBP: systolic blood pressure
DBP: diastolic blood pressure
MAP: diastolic blood pressure
MNCV: motor nerve conduction velocity
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Table 3-2 Raw Data: MAP and NBV
MAP (mmHg)

NBV (mm/s)

Time Point

Control (n=6)

DS (n=6)

Control (n=6)

DS (n=6)

Baseline 1

105±12

94±18

87±15

70±13

SNPearly

81±11

74±13

67±12

50±19

SNPlate

61±7

54±10

38±8

33±14

Baseline 2

101±13

95±17

86±16

75±14

PEearly

125±15

118±20

107±25

100±14

PElate

153±18

141±23

139±37

114±22

DS: insulin-treated experimental diabetes
MAP: mean arterial pressure
NBV: nerve blood flow velocity
SNP: sodium nitroprusside
PE: phenylephrine

Table 3-3 Blood Vessel Count
Nerve Fascicular Arteries

Control (n=6)

DS (n=6)

7±2

7±2

0.4±0.1

0.4±0.1

Total Vessels/mm2

20±4

20±10

Radius of Large Vessels (µm)

21±4

20±2

Total (#)
Area (mm2)

DS: insulin-treated experimental diabetes
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Figure 3-1 ∆ Mean arterial pressure (∆MAP; mmHg) from baseline in the control (□) and
insulin-treated experimental diabetes (■) group during sodium nitroprusside (SNP – NO donor)
and phenylephrine (PE – α1 adrenergic agonist) infusion. Early and late responses reflect ~50 and
100% of the peak effect of the drug.

Figure 3-2 ∆ Nerve blood velocity (∆NBV; mm/s) from baseline in the control (□) and insulintreated experimental diabetes (■) group during sodium nitroprusside (SNP – NO donor) and
phenylephrine (PE – α1 adrenergic agonist) infusion. Early and late responses reflect ~50 and
100% of the peak effect of the drug.
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Figure 3-3 Nerve blood velocity (NBV; mm/s) at a given mean arterial pressure (MAP;
mmHg) in the control (◌, ―l) and insulin-treated experimental diabetes (■, …⁞) group.
The regression equations were calculated for each rodent and averaged separately to
create a two group means.

Figure 3-4 Estimated nerve blood velocity (NBV; mm/s) based on the appropriate
individual linear regression equations in the control (◌; larger circle denotes the mean)
and insulin-treated experimental diabetes (■; larger box denotes the mean) group. *,
Significantly greater than control (P=0.02).
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Figure 3-5 Representative cross-sectional images of the sciatic nerve in the control (A)
and insulin-treated experimental diabetes (B) group. The arrows denote the location of
blood vessels. In each image there are two small and one large blood vessel. Sections
were stained with hematoxylin and eosin.
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3.4

Discussion

The present study employed a rodent model of chronic, moderate hyperglycemia
that resulted in similar blood glucose values as humans with poorly controlled type 1
diabetes. The novel finding of this study was that sciatic nerve vascularization and NBV
responses to changes in MAP remained unchanged in the DS group. Therefore, NBV
would have been similar or possibly elevated in the DS group because conscious blood
pressure was elevated. In spite of these findings, MNCV was reduced in the DS group. In
contrast to the stated hypothesis, NBV was not reduced across a range of MAP. These
data suggest decrements in basal NBF do not precede nerve dysfunction in rats with
chronic, moderate hyperglycemia.
Moderately hyperglycemic rat model
Unlike previous studies (2–6), experimental diabetes did not reduce NBF in the
present study, confirming earlier observations (8,9,11,12). Notably, in the present study
rats were chronically exposed to insulin. Insulin exposure dilates healthy nerve arterioles
(32,33) and insulin treatment attenuates decrements in NBF following diabetes induction
(4,22). Also, unlike previous studies that documented no change (2,3,12) or reduced
(8,34) MAP in rats with chronic severe hyperglycemia, the rats in the DS group in this
study had similar anesthetized and greater conscious blood pressures. The level of
hyperglycemia and insulinemia appear to be important modulators of the blood pressure
response to STZ, as it has been documented that insulin treatment increases blood
pressure in rats with experimental diabetes (35,36). In the present study, insulin treatment
prevented severe hyperglycemia and likely altered the severity and pathophysiology of
disease.
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Perspectives
The present study was the first to our knowledge to examine NBV across a range
of MAP in rats with diabetes. There was no evidence of frank microangiopathy and
because the relationship between MAP and NBV was the same between groups, NBV
was similar and potentially elevated in conscious rats in the DS group. Further, because
MNCV was reduced in the DS group, these data support previous observations that
diabetes-related nerve dysfunction can occur independently of reductions in NBF (8–12).
Further, these data provide evidence that in the absence of microangiopathy, basal NBF
may be elevated in humans with combined poorly controlled type 1 diabetes and
hypertension that are at risk of DPN.
Poor glycemic control increases blood pressure in rats with insulin-treated
experimental diabetes (36) and given the lack of autoregulatory control in in the vasa
nervorum, the ultimate impact of diabetes on NBF would be determined by the balance of
microvascular damage, should it occur, and perfusion pressure. While the current study
did not address neuronal-glucotoxicity or ischemia-induced DPN, it does raise the
possibility that heightened blood pressure and NBF may exacerbate metabolic
complications associated with DPN (11,12,37). Specifically, in rats with diabetes,
increased NBF is associated with elevated nerve fructose and sorbitol concentrations, and
results in deficits in MNCV (9). In humans with insulin-treated diabetes nerve sorbitol
content is inversely related to the number of myelinated fibers (38). Therefore, increased
NBF and glucose metabolism in the nerve may contribute to nerve fiber degeneration and
compromise nerve function.
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The current data conflict with those from Gregory and colleagues (6), who
observed low NBF values in the presence of normal and high blood pressure, in rats with
diabetes. However, they did not examine NBF across a range of MAP in the same
rodents. Also, their rodent model of diabetes did not include insulin treatment and their
rats had ~ two-fold greater blood glucose concentrations, and expressed sciatic nerve
microangiopathy. The presence of microangiopathy in the sciatic nerve may alter the
relationship between MAP and NBF and help explain the divergent findings between
studies (6).
Doppler ultrasound
This study employed high frequency Doppler ultrasound to assess NBV. Recent
developments in high frequency ultrasound technology have enabled the measurement of
blood flow velocity less than 5 mm/s, in superficial arteries as small as 20 µm (39,40). In
previous tests using tissue-mimicking phantoms, arteries as small as 140 µm could be
resolved accurately using B-mode images acquired with a 40 MHz transducer (41).
However, in the present study, the nerve artery was too small to measure its diameter
using B-mode images with 40 MHz ultrasound technology. Thus, epi- or endoneurial
flow could only be assessed indirectly using NBV and VCi. In humans with poorly
controlled diabetes, epineurial blood vessels may be tortuous and subject to arteriovenous shunting (27,42) resulting in a redistribution of NBF towards the epineurial
vasculature. Although endoneurial flow relies on epineurial flow (43), Doppler
ultrasound may not capture all reductions in endoneurial flow. However, the sciatic nerve
vasculature contains feed arteries arising from multiple locations, does not express a
typical capillary plexus, and has been described an anastomotic vascular network (43–
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46). This pattern of tissue perfusion limits the interpretation of gross flow measurements
and underlines a benefit of quantifying exclusive arterial inflow responses.
In the current experiment, failure to detect changes in arterial diameter may result
in underestimated NBF during SNP infusion and overestimated NBF during PE infusion.
This may occur as topical application of SNP causes vasa nerovum dilation (47) and local
delivery of PE causes vasa nervorum constriction (48). However, in the current study
drugs were infused systemically and MAP, rather than SNP or PE, appeared to modulate
NBF. Further, because VCi was similar at all time-points (except SNPlate), any potential
effects of SNP or PE on the vasa nervorum were minimal. In the case of SNPlate, it is
unlikely that SNP constricted the vasa nervorum. A more plausible explanation would be
that the reduction in VCi during SNPlate may have been caused by a sympathetic reflex
pressor response to defend against the ~40 mmHg drop in MAP.
The current data are the first of our knowledge to use Doppler ultrasound to assess
sciatic NBF/autoregulation in a rodent model of diabetes, rendering it difficult to form
direct comparisons. In accordance with previous work (14–19), using a variety of
techniques, we did confirm the absence of autoregulation, suggesting the results obtained
using Doppler ultrasound are comparable with other methods. It is important to note
conflicting results amongst techniques have been documented with laser Doppler
flowometry (4,10), hydrogen clearance (2,8) as well as other methods (9,11,12,37),
regarding the impact of diabetes on NBF control. Nevertheless, the current data support
previous observations that diabetes is associated with either no change (8,10) or
potentially increased (9,11,12) NBF.
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Limitations
Sciatic NBF may be influenced by temperature. The relationship between limb
temperature and NBF may be positive (49) or negative (50) and may have less of an
effect on rats with diabetes (43). In the present study, although rat body temperature was
maintained at 37oC, rat sciatic nerve temperature was not monitored. However, room and
rat core temperature were constant, and NBV at baseline 1 and 2 were similar across
conditions in each experiment, suggesting little impact of non-intervention factors, such
as changes in nerve temperature.
In the present study blood pressure in the conscious state was elevated and by
extension so was estimated NBV in the DS group. However, experimental diabetes often
reduces blood pressure (8,34) and the current blood pressure values collected using the
tail-cuff method were not validated using an arterial catheter in the same conscious
rodents. This issue has been discussed with speculation that severe hyperglycemia may
cause emaciation of the tail and result in artifactually high tail-cuff blood pressure
recordings (51,52). However, using direct methods, it has been documented that insulin
treatment increases blood pressure in rats with experimental diabetes (35,36). More
importantly, in the present study the rats were not severely hyperglycemic and their tails
did not appear emaciated. Also, such issues do not alter the overall conclusion that the
relationship between MAP and NBV remains intact in rats with chronic, moderate
hyperglycemia and reductions in NBF do not always precede diabetes-induced nerve
dysfunction (8–12).
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Conclusion
The novel findings of the current study demonstrated that the absence of
autoregulation persisted in a rat model where moderate hyperglycemia (blood glucose
values similar to those observed in humans with poorly controlled type 1 diabetes) (20)
and elevated blood pressure co-existed. Therefore, elevated blood pressure in conscious
rats with diabetes may result in increased NBF values. Nonetheless, rats in the DS group
exhibited reduced MNCV values. Therefore, reduced NBF cannot be the sole determinant
of DPN. Potentially, elevated NBF may increase glucose delivery to the nerve,
exacerbating neuronal glucotoxicity and impairing nerve function. However, to date the
relationship between NBF and glucose uptake in the nerve remains to be elucidated fully.
Overall, the present study supports the link between poorly controlled insulin-treated type
1 diabetes, hypertension and nerve dysfunction. However, these data suggest that reduced
NBF does not necessarily precede decrements in MNCV. Therefore, in humans with
insulin-treated type 1 diabetes, maintaining normal blood pressure may be important not
only for cardiovascular health, but peripheral nerve health as well.
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Chapter 4

4

« Glucose-stimulated insulin secretion causes a nitric
oxide mediated vasodilation in the blood supply of the
rat sciatic nerve »
4.1

Introduction

Nerve metabolism and function relies heavily on glucose as a substrate and,
therefore, proper glucose and insulin regulation (1–7). Experimental diabetes (ie. chronic
overt hyperglycemia) appears to decrease nerve blood flow (NBF) in rats (1,7,8) and
insulin treatment may partially restore such decrements (1). Unlike skeletal muscle blood
flow, the acute hemodynamic actions of glucose or insulin on NBF control remain
unclear (1,2,6). In skeletal muscle, acute insulin infusion (9,10) or glucose-stimulated
insulin secretion (GSIS) (11,12) stimulates a nitric oxide (NO)-mediated (13,14)
vasodilation. This vasodilation enhances insulin binding and glucose uptake in skeletal
muscle (15). Whether a similar hemodynamic pathway exists in the vasa nervorum
requires further study.
Using video-microscopy, Davidson and colleagues (2) documented insulinstimulated epineurial vasodilation. Applying the laser Doppler method, Biessels and coworkers (1) likewise observed an increase in nerve red blood cell flux following insulin
infusion in streptozotocin induced diabetic rats. These data suggest that glucose may lead
(via insulin stimulation) to neural artery vasodilation.
In contrast, Saini and colleagues (6) observed reductions in NBF following
glucose infusion (3 g/kg). In the aforementioned experiments, insulin increased (2) or
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restored (1) NBF, but GSIS did not (6). Potentially, hyperglycemia attenuates NBF and
insulin-stimulated vasodilation (6). This vasoconstrictor effect of glucose on the nerve
vasculature may relate to adverse effects of hyperglycemia on NO production and
availability (8,16,17) or potentially to a glucose inhibitory effect on adenosine-mediated
dilation (6). The discrepancies between these studies and outcomes also may result from
variations in methods used to measure NBF. Nonetheless, a detailed examination of the
relationship between acute glucose concentration, insulin secretion and nerve arterial
vascular conductance warrants further study.
Therefore, the purpose of this study was to assess the independent vasoactive
effects of acute hyperglycemia and hyperinsulinemia on an index of vascular
conductance in the sciatic nerve vasculature of rats. Based on data by Saini and
colleagues (6), this study tested the hypothesis that glucose infusion will reduce NBF and
vascular conductance through a NO-independent vasoconstrictor mechanism. In contrast
to the hypothesis, the results indicated that glucose stimulated an insulin-mediated, NOdependent dilation in sciatic nerve blood supply.

4.2

Methods

Procedures and Animals
All procedures complied with the Animal Care guidelines and ethics approval
board from The University of Western Ontario. We studied a total of 37 male Sprague
Dawley rats (238-400 g) within four separate and sequential experiments whose
objectives were as follows: 1) determine the effect of glucose on whole leg blood flow
(femoral artery) which includes and emphasizes the skeletal muscle vasculature; 2)
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determine the effect of glucose infusion at two doses (Low; 1 and High; 3 g/kg) on sciatic
nerve vasomotor control; 3) determine if the glucose-stimulated change in nerve vascular
control in #2 above was stimulated by concurrent insulin release; and 4) determine if the
glucose-stimulated and insulin-mediated nerve vasomotor response in objectives #2 and
#3 operated through an NO-dependent mechanism.
To assess the effect of hyperglycemia on nerve vasomotor control independent
from the accompanying insulin response, we implemented a non-insulin secreting rat
model (NIS). In this model rats received a 60 mg/kg streptozotocin (STZ; Sigma-Aldrich,
St. Louis, MO, USA; citrate buffer pH 4.5) injection to impair pancreatic-beta cell
function and attenuate GSIS. Forty eight hours after STZ injection (blood glucose >16
mmol/L), these rats also received a surgically implanted subcutaneous insulin pellet
(Linplant, Linshin, Toronto, ON,CAN; release rate 1 IU/12 h) to reverse hyperglycemia
and maintain normoglycemia. Experimental testing took place ~72 h post implantation of
the insulin pellet.
Surgical Procedures
Surgeries were performed on the animals after a 12-h overnight fast. To achieve
an appropriate surgical depth, rats inhaled isoflurane gas (5%). Thereafter, rats underwent
an intra-peritoneal injection of urethane (50 mg/kg) and α-chloralose (8.0 mg/kg) at the
onset of surgery. After ~ 30 min, the urethane α-chloralose mixture alone maintained
surgical depth for the remainder of the experiment. A warming blanket placed beneath
the animal maintained rat body temperature at 37oC (rectal probe). Catheter insertion
into the right jugular vein facilitated all anaesthetic, glucose (EMD Millipore, Darmstadt,
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HE, Germany,), insulin (Eli Lilly, Toronto, ON, CAN) and L-NG-nitroarginine methyl
ester (L-NAME; Sigma-Aldrich, St. Louis, MO, USA) infusions. A second catheter was
inserted into the right carotid artery and connected to a pressure transducer (PX272,
Edwards Lifesciences, Irvine, CA, USA) to enable continuous blood pressure
measurement. Subsequently, the left femoral artery or sciatic nerve blood supply was
exposed. Sciatic nerve arterial exposure required sciatic nerve separation from
surrounding muscle beds (gluteus maximus and biceps femoris) via blunt dissection (18).
Following separation, parafilm weaved beneath the sciatic nerve and the underlying
tissue provided a landmark to ensure visual consistency throughout the imaging protocol.
Experimental Protocol
Animals were allowed to stabilize for one hour after surgery. Thereafter,
anaesthetized rats underwent one of seven experimental intravenous infusion protocols
over the four experiments outlined above. To establish the effect of GSIS on skeletal
muscle blood flow (i: n=6; 297±37 g) we measured femoral blood velocity (FBV)
following the Low Glucose (50% solution) infusion via the jugular cannula (experiment
1). To examine the effect of GSIS on nerve vasomotor control, we measured nerve blood
velocity (NBV) and mean arterial pressure (MAP) during infusion of Low Glucose (ii:
n=5; 284±30 g), or High Glucose (iii: n=6; 291±57 g) (experiment 2). To establish
whether the endogenous glucose-induced increase in insulin caused the observed effect
(see Results), we assessed NBV and MAP during infusion of High Glucose alone in NIS
rats (iv: n=5; 350±41 g) or during administration of a euglycemic hyperinsulinemic
clamp (EHC; v: insulin: 10 mµ•kg-1•min-1; 0.4UI/mL; n=6; 260±9 g) (experiment 3). To
determine if the GSIS affected nerve vasomotor control through a NO pathway, we co-
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infused High Glucose with L-NAME (non-specific NOS blocker, 15 mg/kg) (vi: n=5;
357±48 g) (experiment 4). In a separate group (vii: n=5; 277±8 g), to assess whether the
effects of L-NAME were exclusively on baseline values or if they inhibited the response
to glucose infusion, L-NAME (15 mg/kg) infusion occurred alone at baseline and
preceded High Glucose infusion by 20 min (experiment 4). In each of the above protocols
(excluding the EHC), isovolumetric saline infusions were also made. In each protocol,
measures of MAP, FBV or sciatic NBV were made at baseline, 5, 10, 20 and 30 min (and
80 min for EHC) following the infusion. The index of vascular conductance (VCi) was
calculated as VCi= peak NBV/MAP.
Details of the Euglycemic Hyperinsulinemic Clamp
For the original description see Defronzo et al. (19). Briefly, an infusion pump
maintained insulin infusion 10 mµ•kg-1•min-1 (0.4 IU/mL) and induced a
hyperinsulinemic state. Using a separate pump, glucose infusion commenced at 20
mg·kg·min-1 (20% solution) to defend euglycemia. Maintenance of euglycemia was made
through adjustments to the glucose infusion rate that, in turn, were based on blood
glucose measurements made every five minutes during the first 20 min, and every 10 min
thereafter.
Data Acquisition and Analysis
The analog blood pressure signal was sampled at 1000 Hz and stored online
(Powerlab; ADInstruments, Colorado Springs, CO, USA). Pulsatile arterial pressure over
~ 10 heart beats was averaged to calculate MAP.
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Blood flow velocity was measured using Doppler ultrasound (Vevo 2100
ultrasound system VisualSonics, Toronto, CA) and a 40 MHz linear array probe
(MS550D) transducer placed superficially along the femoral artery or an artery lying
superficially along the sciatic nerve. The arteries were located using power or colour
Doppler. Thereafter, this segment was studied using duplex imaging mode (frequency of
32 MHz with 100% power, PRF between 4-5 kHz and wall filter of 40-50 Hz) with the
pulsed wave Doppler gate (~0.12 mm width) positioned over the site of high power
Doppler signal (insonation angle of 60°). The smallest vessels that could be detected in
B-mode images acquired using the 40 MHz linear array probe were ~140 µm diameter
(20). Based on the width of the power Doppler image, it has been approximated that the
size of a sciatic supply artery vessel is ~70 - 80 µm. Moreover, the B-mode caliper
resolution was ~15 µm/pixel. Therefore, insufficient resolution existed for confident
measurements of either femoral or nerve arterial diameter changes that might have
occurred in this study. Nonetheless, the greatest vasomotor changes occur downstream in
the microvascular bed and these changes will form the dominant contribution to total
changes in flow velocity through the insonated vessel segment. Therefore, blood flow
velocity represents our surrogate for blood flow volume.
Blood samples obtained from the arterial catheter line enabled measurements of
glucose (FreeStyle Lite, Abbot Diabetes Care, Alameda, CA, USA) and serum insulin
(enzyme linked immunosorbent assay kit for human and rat insulin; ALPCO Diagnostics,
Salem, NH, USA) concentrations.
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Statistics
Statistical analyses were performed using Sigma Stat for Windows (version 8.0).
Paired two-tailed t-tests were used to test the effect of infused agent on NBV and MAP
(baseline versus peak response) for within-group comparisons. The interaction effect of
group and time on the glucose, insulin and VCi changes were assessed using a mixed
model (one-factor repetition) ANOVA. Where necessary, post- hoc Tukey tests
determined the location of significance. The significance level was set at P<0.05. Data
are presented as mean ± SD.

4.3

Results

General observations
Blood glucose and insulin concentrations: Glucose infusion produced a dosedependent rise in blood glucose concentration (3 >1 g/kg; P<0.001; Table 4-1). Glucose
concentration in the NIS group following High Glucose surpassed the measuring range of
the glucometer (>32 mmol/L). Insulin concentration in the High Glucose (3 g/kg) and
hyperinsulinemic clamp groups exceeded those observed in the Low Glucose (1 g/kg)
and NIS groups (P<0.001; Table 4-1).
Nerve blood velocity and mean arterial pressure
Compared to their respective baseline levels, sciatic nerve NBV was greater in i)
High Glucose, ii) High Glucose + L-NAME, and iii) insulin, (P≤0.05; Table 4-2). In all
cases L-NAME significantly elevated MAP (P≤0.05; Table 4-2).
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Experiment 1: Impact of glucose on femoral blood velocity, mean arterial pressure and
femoral vascular conductance
In the femoral artery, infusion of Low Glucose increased FBV from 223±60 mm/s
at baseline to 432±94 mm/s at peak (P=0.001) with no change in MAP (baseline=87±17
vs peak=94±19 mmHg; P=0.153). Consequently, femoral VCi increased from 2.7±0.8
mm•s-1•mmHg-1 at baseline to 4.8±1.5 mm•s-1•mmHg-1at peak (P=0.007; Figure 4-1).
Experiment 2: Effect of glucose infusion at Low and High doses on sciatic nerve
vasomotor control
Compared to baseline, Low Glucose did not alter VCi. However, High Glucose
infusion increased VCi above baseline (P<0.001; Figure 4-2).
Experiment 3: Determine whether glucose stimulates an insulin-dependent or
independent dilation
First, the nerve arterial vascular response to hyperglycemia was measured in the
NIS group. In this model, glucose does not stimulate insulin secretion and insulin
concentrations remain stable (pellet release rat1 IU/12). Compared with baseline, we
observed no change in VCi following High Glucose infusion (P=0.66; Figure 4-3).
Second, the nerve arterial vascular response was assessed during the euglycemic
hyperinsulinemia clamp (EHC). A group x time interaction (P=0.003) was observed
where the EHC caused an increase in VCi compared to both baseline EHC (P<0.001) and
the peak NIS value (P=0.004; Figure 4-3).
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Experiment 4: Determine if the glucose-mediated and insulin-dependent nerve vasomotor
response was dependent upon NO production
This experiment examined whether NO mediated the glucose-stimulated insulindependent dilation. The addition of L-NAME 20 min pre-, or co-infused with, High
Glucose abolished any increase in VCi induced by High Glucose alone (P>0.2; Figure 44). A group x time interaction (P<0.001) was observed where, compared with other
conditions, High glucose alone stimulated increases in VCi (all comparisons P≤0.011;
Figure 4-4).
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Table 4-1 Glucose and Insulin Concentrations
Glucose (mmol/L)

Insulin (ulU/mL)

Group

Baseline

10 min

30 min

Baseline

10 min

Low Glucose
(1 g/kg; n=5)

5.0±0.9

11.9±2.2^§

6.4±0.7

8±2

43±19^

High Glucose
(3 g/kg; n=6)

5.0±0.9

29.1±2.5^§*

16.2±2.9^§*

10±7

182±42^*†

High Glucose
NIS (n=5)

4.6±1.5

>32 ^§*¥a

>32^§*¥a

38±17

43±29

EHC (n=6)

5.3±0.8

5.6±1.4

5.2±1.0

24±15

215±9^*†b

Values are Mean ± SD.
NIS: non-insulin secreting
EHC: euglycemic hyperinsulinemic clamp
^Significantly greater than baseline (within group comparison; P≤0.01)
§
Significantly greater than the EHC group (P<0.001) at the same time point
*Significantly greater than the Low Glucose dose (P<0.001) at the same time point
†
Significantly greater than the NIS group (P<0.001) at the same time point
¥
Significantly greater than the High Glucose dose (P<0.001) at the same time point
a
Too high for the glucometer to measure (>32 mmol/L; input 32 mmol/L for stats)
b
Insulin sample acquired at 80 min
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Table 4-2 NBV and MAP
NBV (mm/s)
Group

MAP (mmHg)

Baseline

At Peak VCi

Baseline

At Peak VCi

Low Glucose
(1 g/kg; n=5)

83±30

103±24*

93±27

99±38

High Glucose
(3 g/kg; n=6)

82±48

138±64*

89±24

76±24

High Glucose
NIS (n=5)

62±19

73±21

82±8

86±6

75±30

167±62*

78±14

77±12

81±23

130±36*

81±16

132±24*

59±5

69±20

110±33

146±24*

83±42

110±45

99±28

110±29

86±36

86±38

84±16

87±18

EHC clamp (n=6)
High Glucose +
L-NAME
(15 mg/kg; n=5)

L-NAME alone
(n=5)
High Glucose
added to L-NAME
(n=5)
Isovolumetric saline
infusion (n=6)

Values are Mean ± SD. *, Significantly greater than baseline of the same protocol
(P≤0.05).
NBV: nerve blood flow velocity
MAP: mean arterial pressure
VCi: index of vascular conductance
NIS: non-insulin secreting
EHC: euglycemic hyperinsulinemic clamp
L-NAME: L-NG-nitroarginine methyl ester
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Figure 4-1 Femoral artery index of vascular conductance (VCi; mm•s-1•mmHg-1) preand post- infusion of Low Glucose (1 g/kg). *, Significantly greater than baseline
(P=0.007).

Figure 4-2 Sciatic nerve arterial index of vascular conductance (VCi; mm•s-1•mmHg-1)
pre- and post- Low (1g/kg) and High (3 g/kg) Glucose infusions. *, Significantly greater
than baseline (P<0.001).
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Figure 4-3 Sciatic nerve arterial index of vascular conductance (VCi; mm•s-1•mmHg-1)
pre- and post- hyperglycemia+euinsulinemia (NIS) and euglycemia+hyperinsulinemia
(EHC). *, Significantly greater than corresponding baseline and peak NIS (P≤0.004).

Figure 4-4 Sciatic nerve arterial index of vascular conductance (VCi; mm•s-1•mmHg-1)
pre- and post- glucose and L-NAME infusions. *, Significantly greater than
corresponding baseline, High Glucose (3g/kg) co-infused with L-NAME (15 mg/kg), LNAME alone and High Glucose infused 20 min following L-NAME (P≤0.011).
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4.4

Discussion

The major new findings of the current study are: i) glucose infusion did not cause
a decrease in VCi, ii) High, but not Low, Glucose resulted in increases in VCi (~120%
from baseline), iii) GSIS mediated the nerve arterial dilation in response to glucose
infusion, and vi) GSIS-mediated dilation was caused by a NO mechanism. These findings
do not support the hypothesis that acute hyperglycemia produces vasoconstriction in the
rat sciatic nerve arteries, as per earlier results (6). Rather, the findings indicate that the
sciatic nerve vasculature reacts similarly to skeletal muscle by vasodilating with glucose
infusion through a NO mechanism in response to the acute insulinemic response.
Experiment 2: Glucose infusion increased VCi
The current data conflict with those of Saini and co-workers (6) who observed a
reduction in NBF following the same intravenous glucose infusion protocol (3 g/kg).
Both studies used Sprague-Dawley rats and MAP responses appear to be similar.
However, we performed measurements at 0, 5, 10, 20 and 30 min following glucose
infusion, whereas Saini and colleagues (6) took measurements at 0, 15, 30, 45, 60, 90 and
120 min following glucose infusion. The peak glucose values obtained following High
Glucose (3 g/kg) infusion were ~three fold greater in our experiment (~ 30 mmol/L) than
in the earlier study (~10 mmol/L) (6). The reason for this difference remains unclear.
Conceivably, insulin secretion would be greater in the current study due to the greater
glucogenic stress. Insulin values are not known from this earlier study and independent
manipulation of blood glucose and insulin concentrations were not performed. In
addition, in the current study, the use of fixed probe Doppler ultrasound system limited
NBF velocity measures to a single segment of a superficial nerve artery. Alternatively,
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Saini et al. (6) used laser Doppler to detect net sciatic nerve vascular flux. This measure
of flux represents the net signal from all red blood cells flowing in any direction. The
sciatic nerve contains feed arteries arising from multiple positions (for example via
gluteal and popliteal arteries) located primarily at the nerve junctions (21–23). Such an
arrangement led to the proposition of bidirectional flow in the nerve (i.e. arteries
traveling in opposite directions along the same segment of the nerve) , as well as the
presence of arterial-venous anastomoses (21–23). If this scenario exists, measures of
blood flow flux in a large region of the nerve may not capture arterial inflow responses.
The combined methodological differences make it difficult to compare results between
the current and previous studies.
Experiment 3: insulin not hyperglycemia stimulated the rise in VCi
The novel findings from this experiment on the blood supply of the sciatic nerve
compliment previous data (1,2) that suggest acute insulin administration increases NBF.
Biessels and colleagues (1) speculated that the effect of insulin to increase NBF may
relate to either a reduced glucose-stimulated vasoconstriction or perhaps insulin itself
exhibits vasodilatory properties. Here we demonstrated that GSIS produced a dominant
dilatory response in the sciatic nerve vasculature.
Using hydrogen clearance, reductions in basal NBF have been observed following
chronic uncontrolled hyperglycemia (7). Employing a similar model of hyperglycemia,
Biessels and colleagues (1) reversed decrements in basal NBF partially with insulin
treatment. Specifically, acute insulin treatment restored basal NBF in chronically
hyperglycemic rats to ~85% of healthy control values. In the present experiment the
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insulin infusion rate was less than that used by Biessels and colleagues (1) but,
nonetheless, a ~50% greater vasodilation was observed. Importantly, Sprague-Dawley
rats were used in the current study, rather than Wistar rats, as used previously. Finally,
the rats used here were not subjected to prior chronic hyperglycemia, a procedure that
may impair endothelial function and NO production (8,17,24).
Experiment 4: L-NAME infusion attenuates GSIS-mediated rises in VCi
Previous studies report a role for insulin, acetylcholine (2), eNOS (8) and nNOS
(17) in sciatic nerve arterial vascular control. Therefore, this study included an
examination of the potential contributions of NO to the GSIS dilatory effect. The
evidence that L-NAME, given before or with glucose, abolished the glucose-stimulated,
insulin-mediated dilation points to an important role for NO in this response. Taken
together, it appears NO influences NBF control and the vasodilatory response to
combined glycemic and insulinemic stress. Whether insulin and glucose act
synergistically to stimulate a NO-mediated dilation remains unclear. A study conducted
by Oomen et al. (25) documented a trend towards enhanced skin blood flow following
hyperglycemia + hyperinsulinemia compared with euglycemia + hyperinsulinemia in
Type I Diabetic participants suggesting an interaction may occur. Nonetheless, despite
differences in circulating concentrations of glucose between the High Glucose infusion
(~30 mmol/L) and the EHC (~5 mmol/L) condition in the present study, GSIS and insulin
infusion resulted in comparable sciatic nerve arterial vasodilation. Potentially the
combination of elevated glucose and insulin enhances any vasodilatory actions; but this
question requires further study.
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Perspectives and Significance
The current study highlighted the independent contributions of insulin and
glucose to NBF control under healthy conditions and clarifies earlier observations (1,2)
regarding the potential vasodilatory actions of insulin in the rat sciatic nerve vasculature.
In particular, insulin appears to vasodilate the blood supply of the sciatic nerve through
an NO-mediated mechanism.
These results may have particular relevance to altered nerve function in diabetes.
In the context on type I and II diabetes, the absence of chronic circulating insulin (1,7,8)
or alternatively, vascular insulin resistance in the vasa nervorum (2) may contribute to
impaired NO signaling and help explain previously observed decrements in sciatic NBF
and nerve function. Experimental diabetes or uncontrolled hyperglycemia appears to
reduce NBF and impair nerve function in rats (1,7,8). Whether this occurs as a result of
hyperglycemia or hypoinsulinemia remains uncertain. Insulin treatment may partially
restore NBF and nerve function (1), but these adaptations occur alongside reductions in
blood glucose concentration rendering it difficult to isolate the exclusive effects of
insulin. Whether stable basal circulating insulin concentrations (similar to the NIS
group), or the fluctuating insulin concentrations resulting from pulsatile insulin secretion,
cause differential effects on nerve health requires further study.
In the present study, NO inhibition alone did not alter baseline vascular
conductance. Instead, NO inhibition impaired GSIS-mediated vasodilation. If basal
insulin concentrations contribute to the maintenance of basal NBF, the mechanism may
be NO-independent. Alternatively, numerous mechanisms may operate in conjunction
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with some degree of redundancy to maintain basal NBF during NO inhibition.
Attenuated vasodilation during NO inhibition suggests that the sciatic nerve vasculature
may operate similarly to skeletal muscle vasculature (15), in that the hemodynamic
actions of insulin may serve to enhance insulin binding and perpetuate any downstream
effects.
Likely, both chronic insulin concentrations and insulin-mediated vasodilation
serve metabolic and vascular functions to preserve neural health. Elucidating their
independent contributions to nerve health is of particular importance when evaluating the
efficacy of various insulin delivery therapies (for insulin-dependent diabetes). For
example, use of a continuous insulin delivery system, such as the insulin pump, may
preserve vasa nervorum health to a greater extent than conventional insulin injections.
Considering the current data and reports that indicate a role for insulin in the maintenance
of basal (1) and vasomotor control of NBF (2), the hemodynamic actions of insulin must
be considered when studying the vascular etiology of peripheral neuropathy in diabetes.
Considerations
Although core temperature was maintained at 37oC, sciatic nerve/limb
temperature was not recorded. Previously, Kihara and co-workers (26) demonstrated a
positive relationship between limb temperature and sciatic NBF. Presumably, in the
current experiment exposure of the sciatic nerve may have cooled the surrounding tissue
and reduced NBF velocity. However, any effects of cooling likely took place during the
stabilization period as baseline conductance values were similar between groups and
blood flow velocity did not decrease during the baseline period. Further, during all
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protocols, the index of conductance either remained unchanged or increased. While the
possibility remains that limb cooling may have attenuated the dilatory responses, this
occurrence would not affect the overall conclusions of the current study.
The exact isoform of nitric oxide synthase was not determined in the current study
as L-NAME acts as a non-selective NOS inhibitor. Although insulin stimulates the
endothelial NOS pathway in skeletal muscle arterioles (13,14), evidence suggests both
endothelial (2,3,8) and neuronal (17) NO may serve a role in NBF control. The current
approach may affect both of these sources of NO but separate roles for endothelial,
neuronal or inducible forms of NO in the insulin-dependent dilation remain uncertain.
Assuming no change in arterial diameter, the Doppler ultrasound method reflects
an effective technique to detect sciatic nerve arterial flow waveforms and changes in
blood flow (27). The advantage of this method includes quantifiable changes in flow and
waveform patterns through arterial segments, excluding venous contributions to overall
flow flux or hydrogen clearance. However, we can only measure the Doppler signal on a
single artery at a time. Moreover, the inability to obtain arterial diameters forced us to
rely on blood velocity measurements alone as the analog of changes in total flow. This
approach, often used in studies of cerebral blood flow velocity patterns (28–30), assumes
the diameter of the interrogated vessel does not change such that any changes in velocity
reflect events happening to the downstream vascular bed. Certainly, the validity of this
assumption requires confirmation in the sciatic nerve arterial network. Nonetheless,
failure to capture any local dilation (ie. increases in arterial diameter) in interrogated
supply vessel would underestimate the overall dilator responses under investigation in the
current study, a limitation that does not alter the overall conclusions.
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Conclusion
This experiment demonstrated that glucose infusion stimulates an insulindependent NO-mediated dilation along the superficial artery of the sciatic nerve. In
addition, increasing the glucose infusion from 1 to 3 g/kg enhances the vasodilatory
response. Lastly, glucose-stimulated insulin secretion and insulin infusion elicit a similar
relative vasodilation.

107

4.5
1.

References

Biessels GJ, Stevens EJ, Mahmood SJ, Gispen WH, Tomlinson DR. Insulin
partially reverses deficits in peripheral nerve blood flow and conduction in
experimental diabetes. J. Neurol. Sci. 1996;140:12–20.

2.

Davidson EP, Coppey LJ, Calcutt NA, Oltman CL, Yorek MA. Diet-induced
obesity in Sprague – Dawley rats causes microvascular and neural dysfunction.
Diabetes. Metab. Res. Rev. 2010;26:306–18.

3.

Coppey LJ, Gellett JS, Davidson EP, Yorek MA. Preventing superoxide formation
in epineurial arterioles of the sciatic nerve from diabetic rats restores endotheliumdependent vasodilation. Free Radic Res. 2003;37(1):33–40.

4.

Field RA, Adams LC. Insulin response of peripheral nerve. Effects on glucose
metabolism and permeability. Medicine (Baltimore). 1964;43(2):275–9.

5.

Kihara M, Zollman PJ, Smithson IL, Langerlund TD, Low PA. Hypoxic effect of
exogenous insulin and diabetic peripheral nerve on normal. Am J Physiol
Endocrinol Metab. 1994;29:980–5.

6.

Saini AK, Arun KHS, Kaul CL, Sharma SS. Acute hyperglycemia attenuates nerve
conduction velocity and nerve blood flow in male Sprague-Dawley rats: reversal
by adenosine. Pharmacol. Res. 2004;50(6):593–9.

7.

Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in
the sciatic nerves of rats with experimental diabetic neuropathy. Brain.
1984;107:935–50.

8.

Maxfield EK, Cameron NE, Cotter MA. Effects of diabetes on reactivity of sciatic
vasa nervorum in rats. J. Diabetes Complicat. 1997;11(1):47–55.

9.

Abramson DI, Schkloven N, Margolis MN, Mirsky IA. Influences of massive
doses of insulin on peripheral blood flow in man. Am J Physiol. 1939;128:124–32.

108

10.

Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of insulin in rat skeletal
muscle. Evidence for capillary recruitment. Diabetes. 1997;46(9):1381–8.

11.

Baron AD, Laaksof M, Brechtel G, Hoit B, Watt C, Edelman SV. Reduced
postprandial skeletal muscle blood flow contributes to glucose intolerance in
human obesity. J. Clin. Endocrinol. Metab. 1990;70(6):1525–33.

12.

Vincent MA, Clerk LH, Lindner JR, Price WJ, Jahn LA, Leong-poi H, et al. Mixed
meal and light exercise each recruit muscle capillaries in healthy humans. Am J
Physiol. 2006;290:E1191–E1197.

13.

Steinberg H, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated
skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to
increase nitric oxide release. J. Clin. Investig. 1994;94:1172–9.

14.

Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide
release accounts for insulin’s vascular fffects in humans. J. Clin. Investig.
1994;94:2511–5.

15.

Baron AD, Steinberg H, Brechtel G, Johnson A. Skeletal muscle blood flow
independently modulates insulin-mediated glucose uptake. Am J Physiol.
1994;29:E248–E253.

16.

Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose
scavenging of nitric oxide. Am. J. Physiol. Renal Physiol. 2001;280(3):F480–
F486.

17.

Ii M, Nishimura H, Kusano KF, Qin G, Yoon Y, Wecker A, et al. Neuronal nitric
oxide synthase mediates statin-induced restoration of vasa nervorum and reversal
of diabetic neuropathy. Circulation. 2005;112:93–102.

18.

Uysal CA, Mizuno H, Hyakusoku H. Sciatic nerve anatomy in rat re-visited: a
more proximal intervention. J Plast Reconstr Aesthet Surg. 2009;62(6):847–9.

109

19.

DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–
E223.

20.

Moran CM, Pye SD, Ellis W, Janeczko A, Morris KD, McNeilly AS, et al. A
comparison of the imaging performance of high resolution ultrasound scanners for
preclinical imaging. Ultrasound Med. Biol. 2011;37(3):493–501.

21.

Adams WE. The blood supply of nerves I. Historical review. Anatomy.
1942;76:323–41.

22.

Bell MA, Weddell AG. A descriptive study of the blood vessels of the sciatic
nerve in the rat, man and other mammals. Brain. 1984;107:871–98.

23.

Zamir M, Twynstra J, Vercnocke AJ, Welch I, Jorgensen SM, Ritman EL, et al.
Intrinsic microvasculature of the sciatic nerve in the rat. J Peripher Nerv Syst.
2012;17:377–84.

24.

Makimattila S, Virkama¨ki A, Groop P-H, Cockcroft J, Utriainen T, Fagerudd J, et
al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via
different mechanisms in insulin-dependent diabetes mellitus. Circulation.
1996;94(6):1276–82.

25.

Oomen PHN, Kant GD, Dullaart RPF, Reitsma WD, Smit AJ. Acute
hyperglycemia and hyperinsulinemia enhance vasodilatation in Type 1 diabetes
mellitus without increasing capillary permeability and inducing endothelial
dysfunction. Microvasc. Res. 2002;63(1):1–9.

26.

Kihara M, Schmelzer JD, Kihara Y, Smithson IL, Low PA. Efficacy of limb
cooling on the salvage of peripheral nerve from ischemic fiber degeneration.
Muscle Nerve. 1996;19(2):203–9.

27.

Twynstra J, Medeiros PJ, Lacefield JC, Jackson DN, Shoemaker JK. Y1R control
of sciatic nerve blood flow in the Wistar Kyoto rat. Microvasc. Res.
2012;84(2):133–9.

110

28.

Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL. MRI Measures of
Middle Cerebral Artery Diameter in Conscious Humans During Simulated
Orthostasis. Stroke. 2000;31(7):1672–8.

29.

Valdueza JM, Balzer JO, Villringer A, Vogl TJ, Kutter R, Einhäupl KM. Changes
in blood flow velocity and diameter of the middle cerebral artery during
hyperventilation: assessment with MR and transcranial Doppler sonography. Am.
J. Neuroradiol. 1997;18(10):1929–34.

30.

Schreiber SJ, Gottschalk S, Weih M, Villringer A, Valdueza JM. Assessment of
blood flow velocity and diameter of the middle cerebral artery during the
acetazolamide provocation test by use of transcranial Doppler sonography and MR
imaging. Am. J. Neuroradiol. 2000;21(7):1207–11.

111

Chapter 5

5

« Exercise training enhances insulin-stimulated nerve
arterial vasodilation in rats with insulin-treated
experimental diabetes»
5.1

Introduction

Diabetes leads to several clinical comorbidities including vascular disease and
peripheral neuropathy (1,2). The pathology of diabetes peripheral neuropathy is
multifactorial and often studied in the context of a metabolic or vascular etiology (3).
From a metabolic perspective, experimental diabetes in rats (model for type 1 diabetes
that causes chronic severe hyperglycemia ~20-40 mmol/L) results in increased neuronal
glucose, fructose , polyols, aldose reductase activity, protein kinase C activity and monoenzymatic protein glycosylation as well as a reduction in neuronal myoinositol and
sodium-potassium ATPase activity (3–8). From a vascular perspective experimental
diabetes is linked with reduced endothelial function (9,10) and nerve blood flow (NBF)
(10–16). Together, these factors contribute to nerve dysfunction (11–13,15). Although,
reduced NBF does not always precede diabetes-induced deficits in nerve function
(5,17,18), impaired vasa nervorum reactivity is implicated in peripheral nerve
dysfunction and may be related to altered nitric oxide (NO) signaling or bioavailability
(9,10,16,19–23) as well as enhanced adrenergic-mediated vasa nervorum constriction
(23, 36, 63).
Insulin therapy is a common and effective treatment for type 1 diabetes. In rats
with experimental diabetes, concurrent insulin treatment prevents the decline in NOrelated vasa nervorum reactivity (9). Further, insulin treatment administered one-month
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following diabetes induction partially restores basal NBF and motor nerve conduction
velocity (MNCV) (15). However, in the aforementioned study, insulin treatment alone
did not completely reverse the effects of chronic hyperglycemia. Conceivably, in rats
with experimental diabetes, insulin treatment may restore NBF and vasoreactivity
partially through a NO-related mechanism. In addition to the effects of insulin treatment
on basal NBF, acute insulin administration stimulates epineurial arterial vasorelaxation
and increases sciatic NBF velocity (NBV) in rats (24,25). It is uncertain what compounds
mediate the insulin-induced dilation (21), but glucose-stimulated insulin-mediated
dilation can be prevented by NO synthase (NOS) inhibition (25). The vasodilatory
actions of insulin were documented over 70 years ago (26), and since then it has been
established that insulin-mediated vasodilation occurs through the activation of the
intracellular enzymes phosphatidylinositol 3-kinase (PI3-K) and protein kinase B (Akt),
which phosphorylate and activate endothelial NOS (eNOS) (27,28). How the relationship
between insulin sensitivity and eNOS expression influences peripheral NBF control
remains to be elucidated fully.
Aside from insulin therapy, other therapeutic agents directly or indirectly targeted
towards NO have been used to prevent experimental diabetes-induced reductions in NBF
or vasoreactivity (10,13,19–22,29). Non-pharmacological interventions, such as
concurrent exercise training, have also been used to prevent diabetes-related peripheral
neuropathy (30,31). However, the effects of exercise training on the preservation of NBF
and vasa nervorum reactivity have yet to be established. In skeletal muscle, insulinstimulated vasodilation is impaired by insulin resistance (32), improved by exercise
training (which is known to increase insulin sensitivity) (33) and appears to be mediated
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in part by eNOS (28,34,35) as well as upstream targets PI3-K and Akt (36). Thus, it is
plausible that chronic hyperglycemia-induced impairments in insulin signaling and NOmediated vasodilation (9,10,15,16,37) may be avoided by concurrent exercise training
(38,39).
Previous observations suggest impaired vasa nervorum reactivity is related to
altered NO signaling and peripheral nerve dysfunction (9,10,16,19–23). Therefore, we
tested the hypothesis that insulin-treated experimental diabetes reduces vasa nervorum
reactivity to insulin, as well as decreases sciatic nerve eNOS expression, and that these
alterations would be prevented by concurrent endurance exercise training. To address this
hypothesis we compared control sedentary rats (CS) to rats with insulin-treated
experimental diabetes that were either sedentary (DS) or exercise-trained (DX).
The above question relates to the ability of endurance exercise training to
ameliorate the effects of diabetes on NBF control. However, it does not consider the
impact of diabetes on exercise trained rats alone. For example, in a previous study (33)
where insulin-stimulated NO-mediated vasodilation in the cutaneous vasculature was
studied in sedentary and endurance trained rats with and without experimental diabetes,
relative to their sedentary counterparts, insulin administration (10-4 mol/L) induced
vasodilation in trained rats with diabetes but not trained control rats. These data suggest
insulin-mediated vasodilation may be different in endurance trained rats with and without
diabetes. However, in the aforementioned study the analyses focused on the effects of
trained vs untrained and not the effects of diabetes on exercise training. Therefore, to
assess the effects of insulin-treated experimental diabetes on endurance exercise trained
rats alone, we conducted a secondary study whereby the responses of DX rats were
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contrasted with a control exercise group (CX). This study tested the hypothesis that
insulin-mediated vasa nervorum dilation would be attenuated in DX rats vs CX rats.

5.2

Methods

Study 1
Procedures
All procedures complied with the Animal Care guidelines and ethics approval
board from The University of Western Ontario. Eight-week old Sprague-Dawley male
rats were obtained from Charles River Laboratories (Saint-Constant, Quebec, CA) and
were housed in pairs at a constant temperature of 20±1oC with a 12-hour light/dark cycle.
Rats had ad libitum access to commercial chow (protein=26%, carbohydrate=60%,
fat=14%; enriched with vitamins and minerals; PROLAB RMH 3000, Brentwood, MO,
USA) and water. Upon arrival, rats were divided into three groups; control sedentary
(CS; n=7), insulin-treated experimental diabetes sedentary (DS; n=9) and insulin-treated
experimental diabetes exercised (DX; n=9). Each week all rats were weighed and their
fed state blood glucose was measured (saphenous vein sample). At 10 weeks following
control conditions, insulin therapy or insulin therapy and exercise training, rats were
anesthetised and underwent a euglycemic hyperinsulinemic clamp and NBV was
measured at baseline and every 10 min for 80 min. Following the insulin clamp, final
blood samples were collected, MNCV was measured and the right sciatic nerves were
harvested, flash frozen in liquid nitrogen and (along with the plasma samples) stored at 70oC for later analyses.
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Animals and diabetes induction
To achieve insulin-treated experimental diabetes (i.e. moderately hyperglycemic
state), eight-week-old rats received daily intraperitoneal injections of 20 mg/kg
streptozotocin (STZ; Sigma-Aldrich, St. Louis, MO, USA; citrate buffer pH 4.5) for five
consecutive days. Following the confirmation of two consecutive blood glucose measures
of >18mmol/L, rats received a surgically implanted subcutaneous insulin pellet (Linplant,
Linshin, Toronto, ON, CAN; release rate 1 IU/12 h). Each week, pellet size was adjusted
(increased or decreased) to maintain moderate hyperglycemia (fed-state blood glucose
obtained during dark cycle ~14.5 mmol/L) (42).
Endurance exercise training
Prior to beginning the exercise training protocol, rats were familiarized with
treadmill running. Familiarization consisted of two 15 min incremental treadmill running
exercise sessions. The exercise training protocol consisted of running on a motorized
treadmill at 27 m/min on a 6o incline, for 60 min, 5 days/week for 10 weeks. In healthy
rats, this represented an exercise intensity of ~75-85% VO2max (43).
Surgical procedures
Prior to surgery, rats were fasted for 12 h. They were anesthetized with inhaled
isoflurane gas (4%) and an intra-peritoneal injection of urethane (25 mg/kg) and αchloralose (4 mg/kg). At doses 50 times greater, urethane causes an increase of blood
glucose of ~ 2-3 mmol/L; however, in the present study, the dose of urethane was small
and exogenous insulin during the euglycemic hyperinsulinemic clamp was used to
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stabilize blood glucose concentrations (44). After ~20 min, the isoflurane gas was
removed and the urethane α-chloralose mixture alone maintained surgical depth. To
maintain body temperature at 37oC (assessed via rectal probe) a warming blanket was
placed beneath the animal. To facilitate infusions of anaesthetic, insulin (10 mµ•kg-1•min1

; 0.4 µIU/mL; Eli Lilly, Toronto, ON, CAN) and glucose (20 mg·kg·min-1, 0.2 g/mL;

EMD Millipore, Darmstadt, HE, Germany), a catheter was inserted into the right jugular
vein. To measure continuous blood pressure, another catheter was inserted into the right
carotid artery and connected to a pressure transducer (PX272, Edwards Lifesciences,
Irvine, CA, USA). To measure NBV, the left sciatic nerve was exposed. This required
sciatic nerve separation from surrounding muscle beds (gluteus maximus and biceps
femoris) via blunt dissection (45). To identify and maintain the same nerve segment
throughout the imaging protocol, a thin slice of parafilm (serving as a landmark) was
weaved beneath the sciatic nerve.
Euglycemic hyperinsulinemic clamp
For the original description of the euglycemic hyperinsulinemic clamp see
Defronzo et al. (46). After surgery, all rats were stabilized for ~60 min before beginning
the experiment and mean arterial pressure (MAP) as well as NBV were stable for ~15
min prior to rats undergoing the euglycemic hyperinsulinemic clamp protocol. Briefly,
insulin infusion at 10 mµ•kg-1•min-1 (0.4 IU/mL) was maintained using an infusion pump.
Blood glucose concentrations were sustained using a separate pump. To maintain
euglycemia, blood glucose was infused at a variable rate that was determined by glucose
measures performed every 5 min for the first 20 min and every 10 min thereafter
(FreeStyle Lite, Abbot Diabetes Care, Alameda, CA). Sciatic nerve blood velocity and
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MAP values were recorded at baseline and every 10 min for 80 min. These values were
used to calculate the index of vascular conductance (VCi= NBV/MAP) and area under
the curve with respect to increase above baseline (47) (AUCi; surrogate for total dilation)
throughout the insulin clamp. After the euglycemic hyperinsulinemic clamp experiment,
a final blood sample was collected and plasma samples were stored at -70oC for later
analysis. Plasma insulin (ALPCO Diagnostics, Salem, NH, USA) and norepinephrine
(Biotang, Lexington, MA, USA) concentrations were determined using enzyme-linked
immunosorbent assay kits.
Data acquisition and Doppler parameters
The analog blood pressure signal was sampled at 1000 Hz (Powerlab;
ADInstruments, Colorado Springs, CO, USA). Pulsatile arterial pressure was averaged
over 10 beats to calculate MAP. A 40 MHz high-frequency linear array probe (MS550D,
VisualSonics, Toronto, Canada) and the Vevo 2100 ultrasound system (VisualSonics,
Toronto, Canada) were used to measure NBV. The probe was positioned over the sciatic
nerve and an artery was located using power Doppler. In duplex imaging mode
(frequency of 32 MHz with 100% power, PRF between 4–5 kHz and wall filter of 40–50
Hz) the pulsed‐wave Doppler gate was positioned over the power Doppler signal
(insonation angle of 60°) and this arterial segment was imaged throughout the insulin
clamp. At 40 MHz, this ultrasound system did not have sufficient resolution to measure
changes in the sciatic nerve supply artery diameter in B-mode images. Thus, peak blood
flow velocity (outer envelope of the mean blood flow velocity waveform) represents a
surrogate for blood flow rate.
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Sciatic motor nerve conduction velocity
Sciatic-fibular (peroneal) MNCV was measured following the insulin clamp
protocol. Single, 100 µs square wave pulses were applied directly to the exposed nerve at
the sciatic notch, and separately in the popliteal fossa via a clinical electrical stimulator
(NeuroscanComperio, Compumedics Medical Systems, El Paso, TX, USA). The elicited
compound muscle action potentials (CMAP) were recorded with tungsten electrodes
inserted into the tibialis anterior. Subsequently, CMAP were displayed, stored and
analyzed on a clinical electromyography (EMG) system (NeuroscanComperio,
Compumedics Medical Systems, El Paso, TX, USA). All EMG signals were sampled at
10 kHz and band-pass filtered at 10 Hz to 10 kHz. The MNCV (m/s) was calculated as:
MNCV = distance between stimulation sites/time difference in CMAP latencies.
Sciatic nerve eNOS expression
Following euthanasia, sciatic nerves were harvested and flash frozen in liquid
nitrogen and stored at -70oC for later analysis.
Nerves were homogenized under liquid nitrogen with mortar and pestle,
immersed in ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM sodium chloride, 5 mM
ethylene glycol tetraacetic acid, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
and 1% Triton-X 100) containing protease inhibitors (104 mM AEBSF, 80 µM aprotinin,
2.1 mM leupeptin, 3.6 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64, Pierce Rockford,
IL) and then sonicated. Tissue lysates were centrifuged for 15 min at 14 000 rpm at 4°C.
Supernatant was collected and stored at -70°C until protein concentration was
determined.
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Total protein concentration of samples was determined by Bradford assay.
Thirty-five micrograms of protein from each sample were loaded on a 4% to 10% gel and
separated by SDS-PAGE. Proteins were transferred to polyvinylidene fluoride
membranes and the blocked for 4 h in 5% milk in Tris Buffer Saline +Tween 20 (0.5%)
(TTBS) at 4°C. The membranes were incubated in primary antibody specific for eNOS
(mouse monoclonal anti-eNOS IgG, BD 610297, 1:2000) overnight at 4°C. Membranes
were subsequently incubated with horseradish peroxidase-conjugated secondary antibody
specific for mouse IgG (goat anti-mouse IgG-HRP conjugate, BioRad 170–6516, 1:2000)
for 1h at room temperature. Immunoreactive bands were detected using an Immun-Star
WesternC© chemiluminescent kit (Bio-Rad, Hercules, CA, USA) and imaged with the
ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). To account for loading,
membranes were stripped then incubated in primary antibody specific to ß-actin (Antibeta Actin, abcam ab8227, 1:5000) then secondary HRP (1:20000) and imaged.
Densitometric band analysis was performed with QuantityOne 1-D Analysis Software
(Bio-Rad, Hercules, CA, USA). Quantified protein expression values were normalized to
ß-actin.
Study 2
To examine the effects of insulin-treated experimental diabetes on endurance
exercise training, we conducted a secondary study wherein the DX responses were
compared with a control exercise training group (CX; n=7). The exercise intervention and
experimental protocols were the same in the two groups.
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Statistics
Body mass (at surgery), fed state blood glucose, insulin pellet dose and glucose
infusion rate during the insulin clamp as well as norepinephrine and insulin
concentrations at the end of the insulin clamp were compared using a one-way ANOVA
or independent two-tailed t-tests (Sigma Stat for Windows, version 8.0). These
comparisons were divided into two separate analyses; study 1 (CS rats, DS rats and DX
rats; Table 5-1) and study 2 (CX rats and DX rats).
The effect of group and time on baseline and peak VCi, as well as NBV and MAP
(at baseline and the peak VCi) during the insulin clamp, were studied using a mixed
model ANOVA. The effects of group on area under the curve for VCi during the insulin
clamp, MNCV and the eNOS:β-actin ratio were compared using a one-way ANOVA (CS
rats, DS rats and DX rats) or independent two-tailed t-tests (CX rats and DX rats). Where
necessary a post-hoc Tukeys tests was used to determine the location of significance. A
regression analyses for eNOS:β-actin ratio vs AUC for VCi was constructed and an
adjusted r2 was calculated. All data are presented as a mean±SD and the significance level
was set at P≤0.05.

5.3

Results

Study 1 (CS rats, DS rats and DX rats)
Intervention data
Body mass (at surgery), fed state blood glucose, insulin pellet dose and glucose
infusion rate during the insulin clamp as well as norepinephrine and insulin
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concentrations at the end of the insulin clamp are presented in Table 5-1. The 10-week
average fed-state blood glucose was greater in DS rats and DX rats compared with CS
rats (P<0.001; Table 5-1). The insulin pellet dose was greater in the DS rats compared
with the DX rats (P=0.02; Table 5-1). Average glucose infusion rate was greater in CS
rats compared with DS rats (P=0.01; Table 5-1). There were no statistical differences for
the average glucose infusion rate between DX rats and CS rats or DS rats (P≥0.09; Table
5-1). At the end of the insulin clamp, plasma norepinephrine concentrations were
elevated in the DS rats compared with DX rats (P=0.01; Table 5-1), but the difference in
norepinephrine concentration between DS rats and CS rats did not reach significance
(P=0.09; Table 5-1). Norepinephrine concentrations were not statistically different
between CS rats and DX rats (P=0.36; Table 5-1). Circulating insulin concentrations at
80 min of the euglycemic hyperinsulinemic clamp were the same between CS rats, DS
rats and DX rats (P=0.94).
Euglycemic hyperinsulinemic clamp data
Baseline NBV was similar between CS rats, DS rats and DX rats (P>0.99; Figure
5-1a). In DS rats, peak NBV was greater during the EHC than baseline (P=0.01; Figure 51a). However, peak NBV was attenuated in DS rats compared with CS rats and DX rats
(P<0.01; Figure 5-1a). There were no main or interaction effects for MAP when
comparing CS rats, DS rats and DX rats (P≥0.15; Figure 5-1b). Baseline VCi was similar
between CS rats, DS rats and DX rats (P≥0.68; Figure 5-1c). In DS rats the peak VCi
was greater than baseline (P<0.01; Figure 5-1c). Nonetheless, the peak VCi was
attenuated in DS rats compared with CS rats and DX rats (P≤0.01; Figure 5-1c). The
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AUCi for the VCi throughout the insulin clamp was reduced in DS rats compared with
CS rats and DX rats (P<0.01; Figure 5-1d).
Data collected following the insulin clamp
Motor nerve conduction velocity was reduced in DS rats compared with CS rats
and DX rats (P≤0.01; Figure 5-2b). Expression of eNOS was greater in DX rats compared
with DS rats (P=0.04; Figure 5-2a). There were no differences in eNOS expression
between CS rats and DS rats, or CS rats and DX rats (P≥0.31; Figure 5-2a).
Study 2 (DX rats and CX rats)
Intervention data
Body mass was greater in CX rats vs DX rats (P<0.01; Table 5-1). The 10-week
average fed-state blood glucose was greater in DX rats vs CX rats (P<0.01; Table 5-1).
Average glucose infusion rate was greater in CX rats vs DX rats (P<0.01; Table 5-1).
There were no differences in plasma norepinephrine between CX rats and DX rats
(P=0.71; Table 5-1).
Euglycemic hyperinsulinemic clamp data
There were no group or interaction effects for NBV, MAP or VCi (P≥0.12). There
was a main effect of time for NBV (peak>baseline; P<0.01), MAP (baseline>peak;
P<0.01) and VCi (peak>baseline; P<0.01) in CX rats and DX rats. However, AUCi for
VCi was reduced in DX rats vs CX rats (P=0.03; Figure 5-3d). Group data for NBV,
MAP, VCi are presented in Figure 5-3a, b and c, respectively.
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Data collected following the insulin clamp
Sciatic nerve MNCV and eNOS expression were reduced in DX rats vs CX rats
(P≤0.02; Figure 5-4a and b).
Group data for eNOS expression and AUCi for the VCi during the insulin clamp
The correlation coefficient between eNOS expression and AUCi for the VCi
during the insulin clamp was 0.54 (adjusted r2;N=21; P<0.01; Figure 5-5)
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Table 5-1 General Characteristics
Variable

CS

DS

DX

Body Mass (at surgery; g)

533±43a

461±38

423±58

Fed-State Blood Glucose (mmol/L)

4.4±0.2

15.2±1.1b

15.0±1.6b

NA

6.6±2.7c

3.8±1.5

22±2d

14±5

19±6

129±16

143±6

123±10d

2905±727

3038±717

2971±739

Insulin Pellet (IU/kg)

Avg. Glucose Infusion Rate (mg·kg·min-1)

Norepinephrine at 80 min (pg/mL)

Insulin at 80 min (pmol/L)

a, Significantly greater than insulin-treated experimental diabetes sedentary rats (DS) and
exercise rats (DX) (P≤0.02)
b, Significantly greater than control sedentary rats (CS) (P<0.001)
c, Significantly greater than insulin-treated experimental diabetes exercise rats (P=0.02)
d, Significantly different from DS rats (P=0.01)
Average (Avg)
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Figure 5-1 a) Nerve blood flow velocity (mm/s) at baseline and peak vascular
conductance during the euglycemic hyperinsulinemic clamp in control sedentary (CS;
dark bar) rats, diabetes sedentary (DS; grey bar) rats and diabetes exercise (DX; open
bar) rats. b) Mean arterial pressure (mmHg) at baseline and peak vascular conductance
during the euglycemic hyperinsulinemic clamp. c) Baseline and peak sciatic nerve arterial
index of vascular conductance (VCi; mm•s-1•mmHg-1) measured during the euglycemic
hyperinsulinemic clamp. d) Area under the curve (AUCi) for the VCi (mm•s-1•mmHg1

•min-1) measured throughout the euglycemic hyperinsulinemic clamp. †, Significantly

greater than baseline (P≤0.01). *, Significantly less than CS and DX rats (P≤0.01).
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Figure 5-2 a) Motor nerve conduction velocity (MNCV; m/s) measured following the
euglycemic hyperinsulinemic clamp in control sedentary (CS; dark bar) rats, diabetes
sedentary (DS; grey bar) rats and diabetes exercise (DX; open bar) rats. b) Endothelial
nitric-oxide synthase (eNOS) expression (normalized to β-actin) in the sciatic nerve. *,
Significantly less than CS and DX (P≤0.01). ‡, Significantly greater than DS (P=0.04).
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Figure 5-3 a) Nerve blood flow velocity (mm/s) at baseline and peak vascular
conductance during the euglycemic hyperinsulinemic clamp in control exercise (CX;
hatched bar) rats and diabetes exercise (DX; open bar) rats. b) Mean arterial pressure
(mmHg) at baseline and peak vascular conductance during the euglycemic
hyperinsulinemic clamp. c) Baseline and peak sciatic nerve arterial index of vascular
conductance (VCi; mm•s-1•mmHg-1) measured during the euglycemic hyperinsulinemic
clamp. d) Area under the curve (AUCi) for the VCi (mm•s-1•mmHg-1•min-1) measured
throughout the euglycemic hyperinsulinemic clamp. *, Significantly less than CX
(P=0.03).
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Figure 5-4 a) Motor nerve conduction velocity (MNCV; m/s) measured following the
euglycemic hyperinsulinemic clamp in control exercise (CX; hatched bar) rats and
diabetes exercise (DX; open bar) rats. b) Endothelial nitric-oxide synthase (eNOS)
expression (normalized to β-actin) in the sciatic nerve. *, Significantly less than CX
(P≤0.02).
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Figure 5-5 Linear regression between endothelial nitric-oxide synthase (eNOS)
expression and area under the curve (AUCi) for the index of vascular conductance (VCi;
mm•s-1•mmHg-1 •80 min-1) measured throughout the euglycemic hyperinsulinemic clamp
in control sedentary (CS; ●) rats, control exercise (CX; ◌) rats, diabetes sedentary (DS;
▼) rats and diabetes exercise (DX; ∆) rats. Adjusted r2=0.54; P<0.01.
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5.4

Discussion

In study 1, insulin-treated experimental diabetes had little impact on basal VCi,
but severely diminished the VCi response to systemic insulin infusion and decreased
MNCV. In rats with insulin-treated experimental diabetes, exercise training preserved
vasa nervorum NBV responses, as well as MNCV, at levels observed in the CS group.
Also, in rats with insulin-treated experimental diabetes that exercise trained, eNOS
expression was elevated compared with their sedentary counterparts (DS rats). In study 2
(CX rats and DX rats), diabetes was associated with reduced vasa nervorum
responsiveness to insulin and nerve function. Therefore, in this model, insulin treatment
combined with exercise training attenuated the effects of chronic, moderate
hyperglycemia on vasa nervorum reactivity to insulin and MNCV. However, study 2
demonstrated that in exercise trained rats alone (CX vs DX), chronic, moderate
hyperglycemia reduces the level of insulin-stimulated vasa nervorum dilation and reduces
MNCV.
It is uncertain whether hyperglycemia or hypoinsulinemia causes the reduced
NBF observed common in experimental diabetes. Chronically severe hyperglycemia
often reduces basal NBF (10–16), but conflicting evidence exists (4,17,18,48,49). In the
aforementioned studies linking experimental diabetes with reductions in NBF, chronic,
severe hyperglycemia values in rats (21-43 mmol/L) exceeded representative ranges
observed in humans with insulin-treated type 1 diabetes mellitus. The standard glycemic
status for patients with poorly controlled type 1 diabetes mellitus is ~9% glycosylated
hemoglobin (40), which corresponds to ~13.5 mmol/L blood glucose concentration (41).
Thus, experimental diabetes in rats that emphasizes the pronounced effects of chronic,
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severe hyperglycemia may not represent the insulin-treated, type 1 diabetes mellitus
observed clinically.
Based on VCi (or NBV) in the current study, baseline blood flow values were
similar between insulin-treated experimental diabetes and control groups. This may have
been the result of the chronic insulin treatment used in the present study or, alternatively,
chronic hyperglycemia does not reduce basal NBF (4,17,18,48,49). Acute insulin
administration stimulates nerve arterial vasodilation or relaxation (20, 41), and prolonged
insulin treatment in rats with experimental diabetes can prevent declines in vasoreactivity
(30) and restore decrements in basal NBF partially (8). In study 1, the DX rats received a
reduced insulin (pellet) dose, but achieved the same degree of hyperglycemia as the DS
rats. The effect of hyperglycemia on baseline VCi or NBV may have been reduced in
both DS rats and DX rats, as the blood glucose concentrations observed in the current
study were substantially less than those recorded during previous experimental
diabetes/NBF studies (10–16). Considering blood glucose and basal VCi were similar
between the two groups with diabetes, the smaller insulin dose in DX vs DS rats,
suggests that insulin sensitivity and not total insulin contributes to the maintenance of the
VCi under basal conditions.
In study 1, insulin-stimulated VCi responses were attenuated in DS rats. In
addition, compared with CS rats, DS rats required a reduced glucose infusion rate during
the clamp to maintain euglycemia. Together, these data provide evidence of depressed
insulin sensitivity. Insulin-mediated vasodilation operates through the activation of
intracellular enzymes PI3-K and Akt, and the subsequent phosphorylation and activation
of eNOS (27,28). Therefore, reduced insulin-stimulated nerve arterial dilation in DS rats
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may be explained by an impaired NO signaling mechanism. For example, glucosestimulated insulin-mediated increases in the VCi operate through a NO mechanism (41).
Also, rats with experimental diabetes express impaired NO-mediated vasa nervorum
dilation (9,16), and reductions in basal NBF can be reversed with NO-donor treatment
(19). Likewise, experimental diabetes impairs insulin-mediated vasodilation in the
cutaneous microvasculature, likely through the PI3-K pathway (36). In the current study,
sciatic nerve eNOS expression was not statistically different between CS and DS rats, but
the overall impact of hyperglycemia on upstream eNOS signaling, NO bioavailability and
reactivity were not examined.
Sympathetic overactivity may provide another explanation for the attenuated VCi
response in DS rats. Insulin stimulates the sympathetic nervous system and elicits a
robust norepinephrine response (50,51) and, in turn, norepinephrine can cause nerve
arterial vasoconstriction (16,52). Furthermore, perivascular adrenergic innervation in the
sciatic nerve (53), and vasa nervorum sensitivity to norepinephrine, increases in rats with
experimental diabetes (16). Whether exercise training reduces perivascular adrenergic
innervation in the sciatic nerve, or decreases vasa nervorum norepinephrine sensitivity, is
unknown. Evidence from humans suggests insulin resistance is associated with reduced
norepinephrine clearance (54), consistent with the present observations. Thus, in study
1, increased norepinephrine (potentially the result of the diabetes, the insulin infusion, or
an interaction of these variables) alongside increased responsiveness to adrenergic
activity in the vasa nervorum may have restrained insulin-mediated dilation.
The reduced insulin-stimulated VCi responsiveness in DS rats was abolished by
concurrent endurance exercise training. The ability of insulin to stimulate a greater vasa
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nervorum response in DX rats compared with DS rats may have been influenced by their
enhanced insulin sensitivity (indicated by a reduced insulin dose during the study in DX
rats vs DS rats). To achieve the same level of hyperglycemia in DS rats and DX rats, DX
rats required less exogenous insulin. This suggests DX rats were more responsive to
insulin and supports the findings that when exposed to the same level of
hyperinsulinemia during the clamp, the vasodilatory response to insulin was greater in
DX rats vs DS rats. Alternatively, the elevated sciatic nerve eNOS content or reduced
circulating norepinephrine may help explain the preservation of the insulin-stimulated
VCi response observed in the DX rats of the current study. In rats with experimental
diabetes, exercise training enhances insulin-mediated microvascular vasodilation in
cutaneous tissues, likely through a PI3-K/eNOS mechanism (27,36). Although NO
bioavailability was not assessed in the present study, it is important to note both DX rats
and DS rats were exposed to similar levels of hyperglycemia throughout the study and
were normoglycemic during the insulin clamp. Therefore, any effects of hyperglycemia
on NO bioavailability should have been similar between the two groups.
Significance
By intention, blood glucose values in the current study were similar to clinical
values observed in humans with poorly controlled type 1 diabetes mellitus (49). In study
1, compared with control and DX groups, sedentary rats with insulin-treated experimental
diabetes had reduced insulin sensitivity and attenuated vasa nervorum responsiveness
during the insulin clamp. In addition, MNCV was reduced in DS rats indicating a
possible loss of large myelinated motor units and alterations in nerve physiology
(31,55,56). Therefore, in spite of having similar baseline VCi or NBV values, similar
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blood glucose concentrations, and greater circulating insulin concentrations compared
with the DX group, DS rats displayed impaired nerve function. These data suggest that
basal blood and hemodynamic variables may be inadequate clinical markers of vasa
nervorum health and that functional tests are necessary to detect the onset of decrements
to vasa nervorum and neural function. Furthermore, the current data indicate that
impaired insulin responsiveness and peripheral neuropathy were not caused by reduced
basal NBF, hyperglycemia or hypoinsulinemia, and presumably were the result of a
combination of hyperglycemia and inactivity. Insulin treatment alone was insufficient to
preserve vasa nervorum and neural function in a rat model chronic, moderate
hyperglycemia.
Exercise training appears to counteract the effects of insulin-treated experimental
diabetes on nerve function and vasa nervorum dilation, possibly by increasing insulin
responsiveness, augmenting eNOS expression and altering sympathetic function. With
similar blood glucose, but reduced basal insulin concentrations in DX rats vs DS rats, it
appears the effects of insulin to dilate the vasa nervorum were amplified by exercise
training. Whereas exercise training has been observed to maintain nerve morphology
(including large myelinated motor units) in rats with experimental diabetes (31),
interventions to prevent deficits in vasa nervorum function have focused largely on
pharmacological means (13,21,57–62). The current data suggest exercise training is a
clinically effective treatment to avoid vasa nervorum and nerve dysfunction.
Furthermore, unlike medication, exercise training offers additional benefits that prevent
other chronic diseases and diabetes-related comorbidities as well as promote health and
longevity in populations with and without type 1 diabetes mellitus (63,64).
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Study 2
In exercise trained rats, insulin-treated experimental diabetes attenuates vasa
nervorum reactivity and nerve health. For example, compared with CX rats, DX rats
displayed reduced vasa nervorum responsiveness to insulin (indicated by a reduced AUC
for VCi during the insulin clamp), had reduced MNCV and sciatic nerve eNOS
expression. Therefore, while exercise training is beneficial, it does not abolish the effects
of chronic, moderate hyperglycemia.
Considerations
A limitation in the current study may be that the artery insonated was too small to
resolve accurately with the ultrasound B-mode imaging device. Therefore, it was
assumed that the diameter of the artery did not change between baseline and the insulin
clamp conditions. This may have resulted in an underestimation of the dilatory response.
Also, because Doppler ultrasound measures NBV from a single epineurial vessel,
it may not be representative of total flow. Epineurial arteries may travel along the nerve
or branch into the nerve (61) and become peri- or endoneurial arteries, but these vascular
networks may possess different control features and it was not possible to quantify
endoneurial-specific flow. In humans with diabetes and poor glycemic control, epineurial
blood vessels are often tortuous and subject to arterio-venous shunting (65,66). This may
result in a redistribution of blood flow that favours greater epineurial vs endoneurial
blood flow. Thus, because Doppler ultrasound is limited to a single epineurial vessel, it
may not capture reductions in endoneurial-specific flow. However, the sciatic nerve
contains feed arteries originating from multiple locations that do not necessarily branch
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into a capillary plexus and has been described as an anastomotic vascular network that
may contain bidirectional flow (i.e. arteries traveling in opposite directions along the
same segment of the nerve) (67–69). Such a pattern of tissue perfusion limits the
interpretation of gross flow measurements and highlights the benefit of quantifying
exclusive arterial inflow responses.
Another possible limitation is that nerve temperature may have fluctuated and
influenced the dilatory response to insulin as well as MNCV (70). Kihara et al.(71)
documented a positive relationship between limb temperature and NBF, while Dines et
al.(72) reported an inverse relationship between limb temperature and NBF, with the
effect of temperature being attenuated in rats with diabetes. In the present experiment
room and body temperature were kept constant, but nerve temperature was not recorded.
The exposure of the sciatic nerve may have led to a decrease in limb temperature.
However, any effects of temperature likely occurred during the stabilization period and
would have been consistent between groups. Also, baseline VCi values were similar
between groups and, in spite of nerve exposure and possible limb cooling, all rats
displayed vasodilation.
Also, during the insulin clamp, the total volume load each rat received would
have been different. Insulin infusion rate was based on mass and glucose infusion rate
was variable and based on insulin sensitivity. Notably, CX rats were more insulin
sensitive and required a greater glucose infusion rate to maintain euglycemia. Potentially,
the increased volume associated with the elevated glucose infusion rate may have
contributed to their augmented VCi. However, despite a greater glucose infusion rate in
CX rats, peak NBV and VCi were similar between CX rats and DX rats. Also, volume-
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induced increases in flow velocity would likely occur on account of increased perfusion
pressure, but during the insulin clamp there was a main effect of time (baseline>peak) for
MAP in CX rats and DX rats, suggesting blood pressure decreased. The vasa nervorum
does not autoregulate, but instead responds passively to changes in MAP. Therefore, the
increase in the VCi (increases in NBV that are not caused by increases in MAP) during
the insulin clamp, was likely not the result of the volume load, but instead the
vasodilatory properties of insulin.
Although glucose-stimulated insulin-mediated dilation appears to operate through
a NO mechanism (41), the exact NO-isoform mediating the insulin-dilation is unknown.
The vasa nervorum dilatory response to acetylcholine and insulin may differ (20)
suggesting insulin may function through an eNOS independent pathway. In the present
study, eNOS expression alone was quantified, but upstream targets such as PI3-K were
not. Further, post-transcriptional or translational modifications to eNOS as well as NO
bioavailability were not measured. To our knowledge, no studies to date have elucidated
the contribution of each NO-isoform to insulin-mediated dilation.
Conclusions
Insulin-treated experimental diabetes reduced whole-body insulin sensitivity, insulinstimulated VCi responses as well as MNCV. These effects were offset by concurrent
exercise training in a separate group of rats with insulin-treated experimental diabetes
(DX rats). However, compared to CX rats, DX rats exhibited reduced whole-body insulin
sensitivity, vasa nervorum responsiveness, MNCV and sciatic nerve eNOS expression.
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From this perspective, exercise training is an effective treatment for insulin-treated
diabetes by reducing the need for exogenous insulin and improving neural outcomes.
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Chapter 6

6

« General discussion»
6.1

Key findings

The major contributions of this dissertation were as follows: i) in the absence of
microangiopathy, the combination of insulin-treated experimental diabetes with
hypertension a) may increase nerve blood flow (NBF) and b) results in motor nerve
conduction velocity deficits, ii) glucose-stimulated insulin secretion causes a NOmediated vasodilation, iii) insulin-treated experimental diabetes attenuates insulinmediated dilation in the vasa nervorum, likely the result of an impaired nitric oxide
synthase (NOS) mechanism and iv) in rats with diabetes, exercise training improves vasa
nervorum reactivity to insulin and motor nerve function. Therefore, despite similar or
possibly elevated basal NBF values in rats with poorly controlled type 1 diabetes, vasa
nervorum reactivity to insulin and motor nerve function are impaired. These negative side
effects appear to be prevented by concurrent exercise training.
These findings support work from Zochodne and Ho (1) that suggest reduced
NBF does not always precede nerve dysfunction in rats with type 1 diabetes. However,
that basal NBF was not decreased does not preclude the existence of microvascular
damage. In the present work, the dilatory response to insulin was reduced and sciatic
nerve endothelial NOS (eNOS) expression tended to be less in rats with type 1 diabetes.
Impaired NO signaling has been implicated repeatedly in diabetes-induced vasa
nervorum dysfunction (2–8), but the efficacy of exercise training as a preventative
treatment strategy was unknown. Based on the beneficial effects of exercise training
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observed in the current study and others (9–11), a greater emphasis needs to be placed on
the study of exercise training and diabetes, as well as the implementation of exercise
training programs to protect against adverse cardiovascular and neural outcomes in
patient populations.
Prior to commencing the present dissertation, there was evidence to suggest
experimental diabetes reduced (12,13), had no effect (1) or increased (14) NBF. In all
cases, the aforementioned observations were supported by varying degrees of
physiological evidence including simultaneous nerve dysfunction, but there was no
general consensus with regards to the impact of diabetes on basal NBF. Slight
differences in the degree and duration of hyperglycemia as well as other experimental
factors may have altered the pathophysiology of diabetes-induced vasa nervorum
dysfunction. Such experimental inconsistencies may have contributed to the conflicting
results between studies. The model of diabetes used in the present dissertation attempted
to replicate the blood glucose values observed in humans with poorly controlled insulintreated type 1 diabetes (15). This model of type 1 diabetes did not induce
microangiopathy or alter basal NBF (in the anesthetized sate). However, it did attenuate
vasa nervorum reactivity to insulin and reduce motor nerve conduction velocity.
Therefore, although basal NBF values are likely important, they provide insufficient
information and separate vascular function tests should be performed to assess vasa
nervorum health.
The functional tests used in the current studies included i) the vasa nervorum
response to changes in mean arterial pressure (MAP) as well as ii) the vasa nervorum
reactivity to systemic insulin infusion. Systemic infusions of sodium nitroprusside (NO-
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donor) and phenylephrine (α1-agonist) were used to achieve changes in MAP. In line
with previous work (16–20), NBF did not autoregulate and responded passively to
changes in MAP. A novel finding from this study demonstrated that the relationship
between MAP and NBF was unaltered by insulin-treated experimental diabetes. Given
the greater MAP in the conscious rats with diabetes, NBF may be expected to increase
accordingly. Conversely, in a separate study, the vasa nervorum dilatory response to
systemic insulin infusion was attenuated in rats with insulin-treated experimental
diabetes. Therefore, the mechanisms responsible for accommodating to changes in MAP
are likely unrelated to NOS, as it is a key enzyme implicated in insulin-mediated
vasodilation (9,21,22). From a clinical perspective, because vasoreactivity to insulin and
nerve function were attenuated by insulin-treated experimental diabetes, but the
relationship between MAP and NBF remained intact, functional tests that assess the NO
pathway may be better indicators of vasa nervorum health.
Based on the current observations, the negative impact of insulin-treated
experimental diabetes on vasa nervorum and nerve function were prevented by
concurrent exercise training. This finding was novel, but not unexpected, as the benefits
of exercise training in humans and animals with type 1 diabetes has been welldocumented over the last century (10,11,23–27). Regular exercise improves endothelial
(11) as well as nerve function (25), increases vascular (9) and whole body insulin
sensitivity (26,28) and reduces exogenous insulin requirements. The present work
supports the aforementioned observations and demonstrates that the enhanced
microvascular insulin responsiveness associated with exercise training extends to the vasa
nervorum. In theory, enhanced insulin sensitivity in the vasa nervorum may potentiate
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insulin signaling in the nerve and protect nerve health. This may help explain why
exercise trained rats with diabetes displayed better nerve function than their sedentary
counterparts, in spite of a reduced insulin pellet dose.
Currently, the Canadian Diabetes Association promotes participation in a regular
exercise program. They recommend that individuals with diabetes accumulate a
minimum of 150 min of moderate to vigorous aerobic physical activity as well as 2-3
resistance exercise sessions per week (29). Although they acknowledge that individuals
with diabetes are more susceptible to adverse events associated with exercise
(hypoglycemia, hyperglycemia or other adverse events related to conditions such as,
neuropathy, retinopathy and angina) (10,30,31), they reason that the benefits of regular
physical activity far outweigh the risks associated with physical activity as well as
inactivity (29). They highlight the beneficial effects of exercise training, citing improved
cardiorespiratory fitness (23), slowed progression of neuropathy (24) and decreased rates
of mortality (32). Although there is much work to be done in this area, based on the
present observation, improved vasa nervorum (or sciatic nerve microvasculature)
function could be added to their list.
Although it is generally accepted that regular exercise is advantageous, how
exercise training imparts health benefits requires further study. Granted, this line of
questioning could take many different directions. As it pertains to the current data, there
are a number of follow up experiments that could be helpful in isolating the stimuli for
vasa nervorum and neuronal adaptation, as well as the contribution of exercise-induced
increases in eNOS to improvements in vasa nervorum function.

151

Isolating the stimuli responsible for the observed improvement in vasa nervorum
function is critical to understanding how exercise mediates adaptation and may also help
refine future exercise training prescriptions. In the present work, exercise training
improved insulin signaling and eNOS expression in the vasa nervorum of rats with type 1
diabetes. The mode of exercise used, was continuous aerobic exercise (60 min per day, 5
days per week, for 10 weeks) performed at ~75% VO2 max. This type of exercise would
require repeated sciatic nerve stimulation and skeletal muscle contraction, both of which
increase NBF acutely (33,34). In theory, the repetitive increases in vasa nervorum shear
stress associated with each exercise session may have provided the stimulus for
endothelial adaption (35). In retrospect it would have been wise to include a measure of
vasa nervorum function in the optic nerve, as it may receive a similar amount of
stimulation in both the active and sedentary groups. Therefore, it would have been
possible to determine if the benefits of exercise training occurred as a result of repetitive
increases in shear stress and were limited to the site of direct vasa nervorum stimulation
or if exercise mediates a global effect and extends to all vasa nervorum networks.
In addition, the relationship between eNOS and vasa nervorum function could be
explored further using an eNOS (-/-) knockout mouse model. Comparing the effects of
physical activity in C57B6 vs eNOS (-/-) knockout mice with insulin-treated
experimental diabetes may help elucidate the contribution of exercise-induced increases
in eNOS to vasa nervorum function. However, results from such studies should be
interpreted with caution as the use of transgenic mouse models does not necessarily
represent preclinical or clinical models of human disease accurately.
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6.2

Conclusion

Over the last three centuries, many have upheld the charge of understanding and
explaining the vasa nervorum. Theirs was the task of recording and bestowing
observations to posterity. Basic and complex findings have been combined to form
generalizations regarding vasa nervorum blood flow control and its association with
nerve function (16,17, 36–49). Presently, I have found myself the inheritor of their great
body of work and it has been my duty and pleasure to devote myself heartily to the study
of the vasa nervorum and diabetes. Vasa nervorum and diabetes research emerged and
evolved on different timelines. However, in the last fifty years they have become
irreversibly connected. In recent history, vasa nervorum research has focused on the
relationship between peripheral NBF and nerve function in type 1 diabetes (1,12,14,44).
Though it is clear that glucose and insulin mediate changes in the vasa nervorum, much
debate still exists regarding the overall impact of acute and chronic alterations in
glycemic and insulinemic status on basal vasa nervorum blood flow and blood flow
control (50). However, it is my belief that such controversy is beneficial, as it breeds
scientific scrutiny as well as creativity. With that in mind, my attempts to expand upon
the current understanding have focused on the exploration of the basic tenets of NBF
control (i.e. the absence of autoregulation) in health and disease, as well as the discovery
of new features (i.e. insulin-mediated vasodilation in the vasa nervorum). Here, we have
demonstrated that i) in the absence of microangiopathy, NBF is unaltered by insulintreated experimental diabetes and the combination of diabetes with hypertension may a)
increase NBF and b) results in nerve dysfunction, ii) insulin-treated experimental diabetes
attenuates insulin-mediated vasodilation in the vasa nervorum, likely the result of an
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impaired NOS mechanism and iii) in rats with diabetes, endurance exercise training
preserves vasa nervorum reactivity to insulin and nerve function. On account of greater
insulin sensitivity and sciatic nerve eNOS expression in endurance trained rats with
diabetes, the exercise training-induced restoration of vasa nervorum function is likely
related to improved insulin-mediated eNOS signaling (9). Based on these observations it
is clear that exercise training is critical to the maintenance of vascular and nerve health in
populations with poorly controlled type 1 diabetes.
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Appendices
Appendix A: Streptozotocin induction protocol (rat)
PURPOSE:
To induce type I diabetes in rats
MATERIALS:
Gloves
Lab Coat
Streptozotocin (STZ)
5X Stock Citric Acid/Citrate Buffer
Anhydrous Citric Acid
Sodium Citrate Dihydrate
MilliQ Deionized Water
13M HCl
3 Falcon Tube
Sterile Filter
EQUIPMENT:
Biological Safety Cabinet
Weigh Scale
pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate
ii. 23.8g Sodium Citrate Dihydrate (Sigma)
Mix into iii. 175mL of MilliQ water
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml
mark (pH will move slightly). If satisfied with the pH, adjust volume in a 250 ml
graduated cylinder and filter in a 0.2µm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection
**NOTE Animals should be pre-weighed prior to making up STZ to ensure accurate
amounts of STZ to be prepared.
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of
distilled water filtered through a 0.2µm syringe filter. Check the pH. This gives you
a working concentration of 153 mM
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2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is reached.
3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe
filter as before). If pH is below 4.5, restart.
4. Weigh out an appropriate amount of STZ for the number of animals (see calculations
below) that will be injected in a 15 minute time frame.

Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g
(avg. weight of rats to be injected), you will require a minimum of 40mg.
20mg/kg X 0.2kg = 4mg per animal
The amount of STZ weighed out should be more than the minimum as some solution
will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total (0.048g)
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume).
Shake to dissolve powder (approx. 1min). Sterile filter using a 0.2µm syringe filter.
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution
4mg ÷ 16mg/mL solution = 0.25mL
6. STZ is time dependent and must be used within 15 minutes
Injecting and Follow-Up of the Animals
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of
20mg/mL (in this example, 0.25mL). Do not use anymore STZ solution more than 15
minutes after it has been dissolved in the sodium citrate buffer.
2. Dispose of any container having come into contact with the STZ (in either powder or
dissolved form) into a biohazardous waste receptacle. Dispose of needles into a
sharps container.
3. Return injected rats to their cage. Record the date of STZ injection and add a
biohazard label to the cage (leave biohazard label on cage for at least 3 days
following the last injection).
4. Repeat this procedure the following day.
5. Check blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of >18 mmol. Diabetes should be achieved after 5-8 injections (i.p.
20mg/kg).
Reference:
Low dose STZ induction protocol. Animal Models of Diabetic Complications
Consortium AMDCC Protocols.2003
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Appendix B: Insulin pellet insertion protocol (rat)
MATERIALS:
LinShin LinPlant Insulin Pellet
Rat anesthetic - Isoflurane
Ampicillin
Sterile water
1ml syringe with 25 g needle
10% providone-iodine solution
gauze (or swab)
Tissue forceps
Scalpel handle and blades (or scissors)
Silk suture
Needle drivers
EQUIPMENT:
IsofluoraneAnaesthetic Machine
Hair clippers
Heat lamp
Special Safety:
Must put on lab coat and gloves before handling rodents. Any bite or scratch that breaks
the skin must be thoroughly scrubbed with soap and water (report to Occupational Health
and Safety).
PROCEDURE:
Pellet implantation (for a rat):
1. Anesthetize the animal using the isofluorane machine by placing it in the induction

chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the stopcock
valve so gas reaches the chamber. Keep in chamber until the animal is unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isofluorane to 3%

to maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% providone-iodine solution to the skin, followed

by 70% ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the

puncture site to a depth of at least 2 cm.
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7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse

with saline and insert into the subcutaneous region.
8. Use 1 pellet for the first 350g of body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providone-

iodine solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.

Pellet removal:
1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by

applying 10% providone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the

location of the pellets.
4. Using forceps, remove the pellet. Some connective tissue may need to be cut away

using scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.

References:
http://www.linshincanada.com
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